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N-terminal methyltransferase 1 (NTMT1) is a new protein methyltransferase that catalyzes the 
N-terminal methylation of proteins with a specific N-terminal sequence motif after methionine 
removal. Protein N-terminal methylation plays multiple cellular roles in DNA-protein interaction, 
chromatin segregation, and DNA damage repair. Dysregulation of NTMT1 has been implicated in 
several cancers and developmental disease. Thus, it is vital to identify NTMT1 targets to reveal its 
involvement in various disease pathology. Here, an activity-based substrate profiling strategy was 
developed to uncover the potential substrates of NTMT1. For proof of concept, Hey-SAM, a SAM 
surrogate containing a terminal alkynyl group, was able to alkylate the previously confirmed 
NTMT1 substrate, regulator of chromosome condensation (RCC1), with a high efficiency in the 
presence of wild type NTMT1. The alkylated RCC1 was subsequently labelled with a biotin group 
via Cu(I) catalyzed click chemistry, which allowed its purification by streptavidin beads. This 
strategy was applied to profile NTMT1 substrates from human cell lysates. Human embryonic 
kidney 293FT (HEK293FT) cell line was edited to generate an NTMT1 knockout (KO) variant 
using clustered regularly interspaced short palindromic repeats (CRISPR)-cas9 system, which 
could produce hypomethylated cell lysates specifically for NTMT1. Potential NTMT1 substrates 
were treated with Hey-SAM, labeled with a biotin group, enriched by streptavidin beads, separated 
on SDS-PAGE, digested by trypsin, and identified by LC-MS. Statistical and motif analysis 
revealed 70 putative NTMT1 targets. Among them, three proteins, RCC1, protein SET, and 60S 
ribosomal protein L23a (RL23A) were reported to be NTMT1 substrates previously. Validation of 
selected targets confirmed that polybromo-1 (PB1, peptide analog), SH3 and PX domain-
containing protein 2B (SPD2B, peptide analog), 40S ribosomal protein S14 (RS14), and Obg-like 
ATPase 1 (OLA1) were NTMT1 substrates in vitro. 
  
Methylation of OLA1 was further investigated in vivo using normal and NTMT1 KO 
HEK293FT cells. OLA1 was reported to play multiple roles in several cellular processes including 
centrosome amplification, antioxidant response, heat shock response and cell growth. 
Overexpressed OLA1 in normal cells is dimethylated and this modification is abolished in KO 
cells. These results confirm that NTMT1 is responsible for catalyzing the N-terminal methylation 
of OLA1 in vivo. Moreover, our preliminary study revealed that methylation of OLA1 does not 
alter its subcellular location and catalytic activity as an ATPase in vitro. Further study is in need 
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Chapter 1 - Introduction 
 1.1 Protein N-terminal methylation and protein N-terminal 
methyltransferases 
Protein methylations especially histone methylations have been a focal point for the past two 
decades due to their crucial roles in epigenetics1-2. Protein arginine and lysine methylations are the 
two most well-studied protein methylations3-4. A third type, the protein N-terminal methylation, 
remained unexplored until the discovery of N-terminal RCC1 methyltransferase 1 (NRMT1, 
NTMT1) in 20105-6, though the first case of N-terminal methylation was reported in  19767-8. For 
all three types of protein methylation, S-adenosyl methionine (SAM) acts as a methyl donor and 
is converted into S-adenosyl homocysteine (SAH) after the methyl group is transferred to either 
the side chains of arginine and lysine residues or the N-terminal amino group of the protein. 
Currently, three human protein N-terminal methyltransferases have been discovered, which 
include RCC1 N-terminal methyltransferases 1 and 2 (NRMT1/2, NTMT1/2) and human 
methyltransferase-like protein 13 (METTL13)5, 9-10. Their similarities and differences will be 
reviewed below. 
 1.1.1 Methylation reactions catalyzed by N-terminal methyltransferases 
As shown in Fig. 1.1, the initial methionine of a protein substrate is usually cleaved by an 
aminopeptidase before it undergoes mono-, di-, and trimethylations5. Multiple methylation 
catalyzed by protein N-terminal methyltransferases could proceed with a distributive or processive 
mechanism. While the former mechanism involves the release of intermediates from the enzyme 
prior to the formation of the final product, the latter one does not11. NTMT1 was reported to be a 
distributive trimethyltransferase, because the mono- and dimethylated products were found to be 




Figure 1.1 Protein methylation catalyzed by NTMT1, NTMT2, and METTL13. 
(A) Protein N-terminal methylation catalyzed by NTMT1 and NTMT2 (when X = P, protein can only be 
dimethylated)5; (B) Protein eEF1A1/2 methylation catalyzed by METTL13 (METTL13-C: C-terminal 
domain; METTL13-N: N-terminal domain)10. 
 
NTMT2, an isoform of NTMT1, was initially considered as a monomethyltransferase9. But 
later study revealed that it could also catalyze the di- and trimethylations of few peptide substrates 
with very low catalytic efficiency13. METTL13 was reported as a trimethyltransferase but it differs 
from NTMT1 in that it specifically catalyzes the methylation of elongation factor 1-alpha 1 
(eEF1A, eEF1A1/eEF1A2) using a processive mechanism10. Jakobsson et al. reported that the 
major product of METTL13 catalyzed methylation was trimethylated eEF1A and only negligible 
mono- and dimethylated proteins were detected at various enzyme to substrate ratios (from 0.01-
3 
10), indicating METTL13 undergoes a processive mechanism for methylations10. While NTMT1/2 
can only methylate the N-terminus of their targets (Fig. 1.1A), METTL13 is a dual enzyme (Fig. 
1.1B) which can trimethylate the N-terminus and dimethylate Lys 55 of eEF1A using its C-
terminal and N-terminal domains, respectively.  
 1.1.2 Substrate specificities of N-terminal methyltransferases 
Substrates of the well-characterized N-terminal methyltransferases from different species are 
listed in Table 1. Nearly all the identified substrates of human NTMT1 and yeast YBR261C/Tae1 
share an N-terminal Met-Xaa-Pro-Lys/Arg motif, such as regulator of chromosome condensation 
(RCC1)5, retinoblastoma 15, protein SET5, DNA damage binding protein 2 (DDB2)14, poly (ADP-
ribose) polymerase 3 (PARP3)15, histone H3-like centromeric protein A (CENP-A)16 and 
centromere protein B (CENP-B)17. One exception is the myosin regulatory light chain 9 (MYL9)18, 
which contains an N-terminal Met-Ser-Ser-Lys motif. In addition, peptide-based methylation 
assay reveals that peptides with expanded N-terminal motifs may also serve as NTMT1 substrates, 
suggesting that NTMT1 may have very broad range of substrates (over 300 proteins)19. Though 
METTL13 is a dual methyltransferase, peptide array-based methylation assay demonstrates that it 
is a very specific enzyme towards its substrates eEF1A1/210. The “functional homolog of 
METTL13-C” from yeast, Efm7, is also a dual methyltransferase and exhibits unique substrate 
specificity, however, it differs from METTL13 in three aspects10. First, Efm7 is a dual 
methyltransferase, but it targets the N-terminus of Gly 2 and the side chain of the adjacent Lys 3 
residue20. Second, Efm7 cannot methylate the N-terminal peptide (first ten residues without 
methionine) of eEF1A1, which suggests that the tertiary structure of eEF1A may be important for 
substrate recognition20. And finally, it cannot methylate human eEF1A protein, indicating it may 
be a species specific enzyme20. Taken together, NTMT1/2 recognize an N-terminal motif and may 
4 
have very broad range of substrates, while Efm7 and METTL13 are more substrate specific 
enzymes. 
 
Table 1.1 Substrates of the well-characterized N-terminal methyltransferases.  




YBR261C/Tae16 S. cerevisiae Rpl12ab (MPPKF)6; Rps25a/Rps25b 
(MPPKQ)6 
NTMT1 (NRMT1)5 Homo sapiens RCC1 (MSPKR)5; Retinoblastoma 1 
(MPPKT)5; SET (MAPKR)5; DDB2 
(MAPKK)14; PARP3 (MAPKP)15; CENP-A 
(MGPRR)16; CENP-B (MGPKR)17; MYL9 
(MSSKR)18; 




Efm7 (YLR285W)20 S. cerevisiae eEF1A (MGKEK)20 
METTL1310 Homo sapiens eEF1A1 (MGKEK)10; eEF1A2 (MGKEK)10 
 
 
 1.1.3 Catalytic mechanisms of N-terminal methyltransferases 
Dong et al. and Wu et al. solved the crystal structures of the ternary complexes containing 
NTMT1, substrate peptides and SAH independently (PDB: 5E1B, 5CVD)22-23. Cheng et al. solved 
the crystal structures of NTMT2 in the presence of SAM (PDB: 5UBB), and the ternary complex 
containing NTMT2, substrate peptide and SAH (PDB: 6DUB)13. Crystal structure of METTL13 
C-terminal domain (PDB: 5WCJ)10 was solved by Jakobsson et al. The overall structures of all 
three N-terminal methyltransferases exhibit a typical Rossmann-like fold (Fig. 1.2). NTMT1 and 
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NTMT2 contain a seven β strand sheets surrounded by five α-helixes13. METTL13 contains a 
seven β strand sheets flanked by six α-helixes10.  
 
 
Figure 1.2 Overall structures of NTMT1, NTMT2, and METTL13-C.  
(A) Crystal structure of NTMT1 with SAH (PDB: 2EX4). (B) Crystal structure of NTMT2 with SAM 
(PDB: 5UBB). (C) Crystal structure of METTL13 C-terminal domain with SAH (PDB: 5WCJ). Figures 
were prepared with PyMOL. 
 
The ternary complex (PDB: 5E1B) of NTMT1, RCC1 peptide (SPKRIA) and SAH reveals that 
NTMT1 consists of a substrate binding domain and a Rossmann-like fold domain23. SAH is 
anchored inside by the electrostatic interaction between its carboxylate group and arginine 74 
residue, the stacking interaction between its sugar ring and tryptophan 20 residue, and the 
hydrogen bonding between its adenine group and glutamine 120 residue and the main chain of 
leucine 119 residue (Fig. 1.3)23. In addition, the crystal structure uncovers why a substrate 
harboring an N-terminal Xaa-Pro-Lys motif is preferred for NTMT1. First, the dimethylated 
glycine locates in a narrow pocket which may also be able to hold other small residues (e.g., 
proline, serine, alanine)23. Second, proline 3 is surrounded by a hydrophobic environment formed 
by residues leucine 31, isoleucine 37, tryptophan 136 and isoleucine 214 (Fig. 1.3)23. Moreover, 
the stacking interaction between proline 3 and tryptophan 136 residue (Fig. 1.3) makes proline the 
optimum residue in the third position, which explains why proline 3 is conserved among all the 
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identified substrates23. Third, a positively charged residue in position 4 is crucial for substrate 
recognition due to the hydrogen bonding between lysine 4 and aspartate 177 and 180 residues (Fig. 
1.3)23. In addition, Dong et al. pointed out that a positively charged residue in position 5 is 
preferred because it is in the entrance of a negatively charged channel22. 
 
Figure 1.3 Substrate binding domain of NTMT1.  
Ternary complex of NTMT1, SAH and RCC1 peptide SPKRIA (PDB: 5E1B). SAH is shown in magenta. 
NTMT1 residues are shown in green. Peptide SPKRIA is shown in yellow. Figure was prepared with 
PyMOL. 
 
An SN2 reaction mechanism for methylation has been proposed according to the crystal 
structures22-23. Briefly, N-terminal α amino group of the substrate is deprotonated by water 
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mediated hydrogen bonding network consisting of NTMT1 residues aspartic acid 167, aspartic 
acid 180 and histidine 14022. After that, the deprotonated nucleophilic nitrogen can attack the 
active methyl group of SAM to give the methylated product and SAH.  
 
Figure 1.4 Sequence alignment of NTMT1 and NTMT2.  
NTMT1 and NTMT2 are aligned using online EMBOSS Stretcher (EMBL-EBI) which gives 40% identity 
and 58% similarity. Identical residues are indicated as a vertical line (|); chemically similar residues are 
indicated as double dots (:); chemically different residues are indicated as one dot (.); missing residues are 
indicated as a dash line (-). Conserved residues in substrates binding domain and catalytic domain are 
highlighted in yellow. Asparagine 89 (NTMT2) and its aligned glycine residue (NTMT1) are colored in 
red. 
 
The key residues in substrate binding domain and catalytic domain are conserved in NTMT1 
and NTMT2 (Fig. 1.4), however, unlike NTMT1, NTMT2 is primarily a monomethyltransferase9. 
Based on the ternary structure of NTMT2, SAH and RCC1 peptide SPKRIA, Dong et al. proposed 
that asparagine 89 might be involved in determining NTMT2 as a monomethyltransferase13. 
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Peptide-based activity assay confirmed that NTMT2 N89G mutant was able to dimethylate RCC1 
peptide13. However, the trimethylated RCC1 peptide was not observed, indicating that additional 
residues in substrate binding domain may also participate in determining the catalytic specificities 
of NTMT1/213.  
 1.1.4 Tissue and subcellular locations of N-terminal methyltransferases  
NTMT1 and NTMT2 were reported to locate mainly in cell nucleus based on fluorescence 
signals given by overexpressed GFP tagged proteins in HeLa cells9. This is consistent with the 
subcellular distribution of their substrates (e.g., DDB2, RCC1). One exception is MYL9 which 
primarily is in the cytosol18. According to human protein atlas database, the major location of 
METTL13 is cell cytosol24.  
It was reported that the transcription level of NTMT1/2 messenger RNA (mRNA) quantified 
by quantitative real-time polymerase chain reaction (qRT-PCR) of mouse tissue extracts was low, 
suggesting a low protein expression level of NTMT1/29. The maximum mRNA expression level 
of NTMT1 was detected in brain tissue, and muscle tissue contained the highest mRNA level of 
NTMT29.  
 1.2 Functions of protein N-terminal methylation 
Protein N-terminal methylation has long been believed to regulate protein degradation because 
the introduction of methyl groups may block the protein N-terminus and protect it from digestion 
by aminopeptidases25. The N-terminal methylation of protein RCC1 was discovered in 2007, 
which revealed one novel function of protein N-terminal methylation in regulating protein-DNA 
interaction. Chen et al. reported that Madin-Darby Canine Kidney (MDCK) cells transfected with 
methylation deficient RCC1 (K4Q mutant) exhibited a more diffused distribution pattern of RCC1 
compared to the ones transfected with wild type (wt) RCC1. Transfection of methylation deficient 
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RCC1 ultimately caused the abnormal mitosis5. It was proposed that trimethylation of RCC1 which 
introduced a permanent positive charge on its N-terminus would promote its binding with the 
negative charged phosphate backbone of DNA. Conversely, absence of trimethylation would 
weaken the protein-DNA interaction and result in the diffused distribution of RCC15. 
Similar to RCC1, trimethylation of CENP-B N-terminus was found to enhance its binding with 
DNA17. Sathyan et al. reported that the N-terminal methylation of CENP-A played important roles 
in regulating centromere function and maintaining normal chromosomal segregation16. The 
methylation deficient CENP-A mutant caused the reduced centromere localization of CENP-T and 
CENP-I which are important components of constitutive centromere associated protein network 
(CCAN) and promoted the formation of multipolar spindles16.  
In addition, protein N-terminal methylation was reported to participate in DNA damage repair. 
DDB2 exhibited enhanced cell proliferation ability upon UV light irradiation compared to its 
methylation deficient mutant (K4Q). The methylation deficient DDB2 displayed less nucleus 
localization14. Cai et al. proposed that the N-terminal methylation of DDB2 might affect protein-
protein interactions14, however, the molecular mechanism for its involvement in DNA damage 
repair remains unknown. So far, no readers of methylated DDB2 were reported. 
Moreover, the N-terminal methylation of MYL9 exhibited enhanced transcriptional activation 
of protein intercellular adhesion molecule 1 (ICAM1) compared to its methylation deficient mutant 
(K4Q)18. The molecular mechanism is unclear, but methylation of MYL9 was proposed to enhance 
its interaction with ICAM1 promoter18. 
Functions of eEF1A N-terminal methylation were not well understood. Knockout (KO) of 
METTL13 in HAP-1 cells affected the translation rate of several specific codons10. For example, 
the translation of alanine codons accelerated, while the translation rate of lysine and histidine 
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codons decreased10. So far, eEF1A is the only identified substrate of METLL13 and it would be 
possible that the N-terminal methylation of eEF1A participates in influencing the codon 
translational rates. However, to verify this hypothesis, it would be a good start point to study the 
effects of methylation deficient eEF1A mutant on codon translation. 
Taken together, protein N-terminal methylation plays multiple roles in maintaining cellular 
processes such as regulation of protein-DNA interaction, maintaining normal centromere function 
and chromosomal segregation, participating in DNA damage repair, and affecting amino acid 
codon translational rates.  
 1.3 Phenotypes related to dysregulation of N-terminal methyltransferase 1 
Overexpression of NTMT1 in M. D. Anderson Metastasis Breast cancer 231 (MDA-MB-231) 
cell line resulted in the decreased cell growth rate26. Knockdown of NTMT1 promoted the growth 
of Michigan Cancer Foundation-7 (MCF7) cell line and enhanced the metastatic potential of 
SKBR-3 and MDA-MB-231 cell lines26. All these results suggest that NTMT1 functions as a tumor 
suppressor in human breast cancer cell lines26. Conversely, Shields et al. reported that NTMT1 
knockout in colon cancer HCT116 cell line dramatically reduced the cell proliferation rate, 
indicating that NTMT1 might act as a tumor oncogene in colorectal cancer27. NTMT1 has very 
broad substrates, which may have different expression levels and play distinct roles in different 
tumors and thus caused this contradiction. NTMT1 mutations in human cancer tumors can be 
found from the website of Catalogue of Somatic Mutations in Cancer (COSMIC, 
https://cancer.sanger.ac.uk/cosmic). Most of the mutation sites reported are not key residues for 
substrate binding or catalytic activity. Shields et al. reported that two mutants of NTMT1 (N209I 
in endometrial cancer and P211A in lung cancer) resulted in a much lower catalytic activity 
compared to wt NTMT127.  
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In addition, Bonsignore et al. generated NTMT1 KO mice (Ntmt1-/-) which exhibited abnormal 
phenotypes correlated to double strand DNA damage28. Around 40% of NTMT1 KO homozygous 
mice died in one month after birth and the survived ones showed decreased body size, kyphosis, 
smaller livers and female infertility28. Taken together, dysregulation of N-terminal 
methyltransferases is related to the carcinogenesis promotion and the cause of developmental 
diseases. 
 1.4 Current chemical and biological tools for methylation study 
As protein N-terminal methylation plays multiple functions in organism growth and 
development, it will be of great importance to study their upstream regulators (writers) and 
downstream regulators (readers and erasers). Writers of methylation are the enzymes that catalyze 
this modification and are also called “methyltransferases”. Readers of methylation are the proteins 
which can recognize and bind to the methylation sites. Erasers of methylation are the enzymes 
responsible for removing this modification and are also named as “demethylases”. In addition, 
NTMT1 was predicted to have multiple substrates and only a few of them have been identified. 
Thus, it is essential to uncover more of its substrates to elucidate the functions of this important 
modification. Here, the chemical and biological methods for profiling the upstream and 
downstream regulators are reviewed and organized into four modules: methylation “writers”, 
substrates, “readers” and “erasers”. These approaches may be further applied in the study of N-
terminal methylation. 
 1.4.1 Methylation writers 
The discovery of NTMT1 as an N-terminal methyltransferase was three years later after the 
discovery of RCC1 N-terminal methylation5, 29. NTMT1 was previously named as 
methyltransferase-like 11A (METTL11A), indicating that it may function as a methyltransferase, 
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but its catalytic reaction was unknown. The important roles of RCC1 N-terminal methylation in 
mitosis triggered the discovery of the corresponding methyltransferase, NTMT1. Tooley et al. 
developed an activity-based methyltransferase profiling method in which HeLa nuclear extracts 
were separated into several fractions by hydroxyapatite ion exchange chromatography and each 
fraction was examined for methylation activity5. Each fraction contained hundreds of proteins 
which greatly narrowed down the number of proteins in the candidate pool. Antibody 
immunoblotting-based activity assay and enzyme-linked immunosorbent assay (ELISA) were 
applied as a rapid approach to examine the methylation activity of each fraction and finally, the 
methylation activity was observed in two fractions which were further analyzed by mass 
spectrometry5. Several key elements should be considered for the activity-based profiling 
approach: (a) Various subcellular fractions (e.g., nuclear, membrane, cytoplasmic) should be 
firstly screened for methylation activity to determine the proper fraction for further analysis. 
Tooley et al. only focused on nuclear fraction which eliminated unnecessary work and simplified 
the analysis5.  (b) Multiple protein separation methods such as ion exchange and size exclusion 
chromatography should be applied to limit the number of proteins in one fraction. (c) A sensitive, 
simple and fast methylation assay should be developed to avoid false negative results and tedious 
work. Several sensitive and rapid methylation assays have been developed including fluorescence-
based SAH hydrolase (SAHH) coupled assay12, enzyme coupled ultrasensitive luminescence 
assay30, mass spectrometry (MS)-based methylation assay12, antibody-based immunoblotting5 and 
ELISA5. (d) And finally, high-resolution mass spectrometry (HRMS) coupled with either an ultra-
performance liquid chromatography (UPLC) or a nanoflow liquid chromatography is required for 
the identification of proteins in low quantities as some endogenous enzymes may have very low 
expression levels but high catalytic activities.  
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Moreover, in prokaryotes (e.g., Escherichia coli (E. coli)) or single-celled eukaryotes (e.g., 
yeast) which contain less amount of proteins compared to human or mammals and thus have been 
studied as model organisms for a long time, the activity-based methyltransferase profiling strategy 
is further simplified. For example, Kimura et al. described a reverse-genetics approach in E. coli 
for profiling RNA methyltransferase which catalyzed the N6-methylation of N6-
threonylcarbamoyladenosine (t6A) in transfer RNAThr (tRNAThr)31. The E. coli genomic-deletion 
strains which covered ~50% of E. coli open reading frames (ORFs)31 were analyzed by liquid 
chromatography-mass spectrometry (LC-MS) to screen the existence of N6-methylated t6A 
(m6t6A) in tRNAThr. This modification was only not detected in OCR36 strain, which narrowed 
down the number of candidate enzymes to 2331. The number of candidate proteins was further 
decreased to 10 following bioinformatic analysis, and finally, gene yaeB was identified for coding 
the responsible methyltransferase31. Jackman et al. reported a genomic approach to profile the 
responsible methyltransferase for m1G9 in tRNA from yeast Saccharomyces cerevisiae32. In this 
approach, a yeast strain array constructed by Martzen et al. was used for screening the methylation 
activity33. The array contained 6144 yeast strains and each strain was able to express a specific 
glutathione S-transferase (GST)-tagged yeast protein33. To simplify, 96 strains were grown in a 
pool and 6144 strains were thus divided into 64 pools33. GST-tagged proteins were purified from 
each pool and their methylation activity was examined33. After one-round screen, the number of 
candidate proteins were efficiently narrowed down to 9633. A second-round screen assayed 20 
subpools and a protein coded by YOL093w was finally confirmed to be the relevant 
methyltransferase32. Meanwhile, three human homolog proteins were also identified32. The 
reverse-genetics and genomic approach is simply because the separation of cellular proteins is not 
required as either gene KO strains or a strain expressing an individual protein is accessible. 
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However, one limitation of this approach is that lots of proteins derived from advanced organisms 
do not have their homologs in either E. coli or yeast.  
In addition, METTL13 was identified as an N-terminal eEF1A methyltransferase by co-
immunoprecipitation (co-IP) with eEF1A N-terminal peptide10. Based on the prediction that 
“writers” may bind to their substrates tighter than their products, trimethylated eEF1A peptide was 
used as a control for MS-based quantitative pull-down assay10. Peptides or proteins used for co-
immunoprecipitation are often called “baits” and usually contain a report group which could be an 
affinity tag or a functional group that is ready to incorporate an affinity tag. Affinity tags could be 
a biotin which can be pulled down by streptavidin beads due to their strong interaction (Kd ≈ 10
-14 
M)34 or epitope tags (e.g., Flag-tag, Myc-tag) which can be purified by immunoaffinity resins. 
Jakobsson et al. utilized biotin labeled peptide as a bait for profiling eEF1A methyltransferase10. 
Two key points should be considered for this strategy: (a) One or more controls must be carried 
out at the same time to eliminate false positive results. Parallel biological experiment repeats, and 
statistical analysis are usually required for quantitative MS-based protein identification. (b) The 
bioinformatic analysis may assist to find of the correct enzyme because lots of the proteins 
identified are not methyltransferase and some may even not be biologically relevant. Jakobsson et 
al. reported that 157 proteins were enriched by the bait and 174 proteins were enriched by reference 
peptide10. Without bioinformatic analysis, it would be challenging to examine the methylation 
activity of more than 100 proteins through trial and error.  
Currently, bioinformatics has been a powerful tool in the prediction of putative 
methyltransferases. As more and more methyltransferases are identified and lots of their crystal 
structures are solved, it becomes easier to predict novel methyltransferases based on the conserved 
SAM binding motifs or by full sequence alignment with Basic Local Alignment Search Tool 
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(BLAST)35. Though we cannot directly predict a methyltransferase for a specific target through 
bioinformatic analysis, but it is a powerful tool to provide useful information for further study.  
In summary, four methods including activity-based methyltransferase profiling from human 
cell lysates, reverse-genomic approach, co-immunoprecipitation with substrate peptides as baits 
and bioinformatics have been reviewed. Each method has its own strength and weakness, so it 
would always be wise to think of their limitations and applications to make the best choice. 
Moreover, a sensitive and reliable methylation activity assay or a methylation detection approach 
is required for all four strategies. 
 1.4.2 Methylation substrates 
A widely used approach for substrate profiling is domain or motif searching since the 
substrates usually share some common characteristics for a specific enzyme. For example, most 
of the N-terminal methylated eukaryotic proteins contain an N-terminal Met-Xaa-Pro-Lys/Arg 
motif5. Later, several proteins including DDB2, CENP-A, and CENP-B which harbor the same 
motif were predicted and successfully confirmed as NTMT1 substrates14-16. Moreover, Tooley el. 
al used anti-me3-SPK antibody which specifically recognizes trimethylated Ser-Pro-Lys motif to 
pull down potential NTMT1 targets5. Six proteins harboring the N-terminal motif including RCC1 
and SET were pulled down5. Substrate profiling via immunoprecipitation was also applied in 
identifying arginine methylated proteins36. For example, Boisvert et al. identified 200 new proteins 
as putative substrates for protein arginine methyltransferases through immunoprecipitation with 
specific antibodies against dimethylated arginine in RG-rich sequences36.  
In addition, peptide array has become a very popular tool for profiling methylation substrates 
as it can be rapidly synthesized and applied for high-throughput screening. The rapid synthesis of 
peptide array owed to the invention of solid phase peptide synthesis by Robert Bruce Merrifield, 
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who won Nobel Prize in chemistry for this innovation. Frank et al. reported an approach to 
synthesizing multiple peptides on cellular paper discs simultaneously which made peptide array 
attainable37-38. Peptide array was widely applied in the study of protein arginine and protein lysine 
methylation. Najbauer et al. reported that synthesized peptides with Gly-Arg-Rich (GAR) motif 
were able to be methylated by protein arginine methyltransferases (PRMTs) and inhibited the 
methylation of endogenous hypomethylated substrates, which indicated that substrate proteins 
could be replaced by short peptides for methylation study to some extent39. Later, Wooderchak et 
al. applied peptide array in the study of PRMT1 substrate specificity and concluded that PRMT1 
substrates may be not limited to the ones which harbor the dogmatic “RGG” motif40. Similarly, 
Dhayalan et al. applied peptide array in the study of protein lysine methyltransferase SET7/9 and 
revealed 91 new peptides and 9 non-histone proteins as putative substrates41. Recently, peptide 
array-based methylation assay has been applied in the study of protein N-terminal methylation, 
which expands the N-terminal recognition motif of NTMT1 substrates and more than 300 proteins 
have been predicted as putative substrates19. Although peptides have been widely used for protein 
methylation study, it has to be noted that peptide-based substrate profiling may generate false 
positive or false negative results. For example, yeast Efm7 catalyzed the N-terminal methylation 
of protein eEF1A but was unable to methylate eEF1A N-terminal peptide20, suggesting that the 
protein 3D conformation of eEF1A may be involved in substrate recognition for yeast Efm7. On 
the contrary, methylation on peptides level does not mean the corresponding proteins are true 
substrates because the very flexible peptides may be buried inside of the 3D structure of proteins 




Figure 1.5 Labeling DNA/Protein with SAM analogs. 
(A) Labeling DNA with aziridine cofactors42-43. (B) Labeling DNA/protein with sulfonium-alkyl SAM 
analogs44-48. 
 
Moreover, labeling substrates with a reporter group (e.g., fluorescence tag, affinity tag) via 
chemical approaches has been investigated for two decades. The idea is to introduce a reporter 
group to the substrates through methyltransferase catalyzed group transfer reactions. To achieve 
this, two types of SAM analogs (Fig. 1.5) were designed and synthesized. The first type contains 
an aziridine group and a reporter group42-43, which can directly label the substrate proteins by one 
step methylation reaction. Another type is the sulfonium-alkyl SAMs which will not introduce a 
bulky report group to substrates directly, but instead, the substrate proteins are alkylated with an 
alkynyl or azide group44-48. Through one step Copper-Catalyzed Azide-Alkyne Cycloaddition 
(CuAAC), substrates can be efficiently labeled with a reporter group. CuAAC was also named as 
click chemistry and was concurrently discovered by the group of K. Barry Sharpless and Morten 
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Meldal in 2002 which provides an efficient approach for bond formation between an azide and an 
alkyne49-50. SAM analogs listed in Fig. 1.5 have been applied to label substrates of DNA 
methyltransferases, protein arginine methyltransferases, and protein lysine methyltransferases42-
48. Note that wild type methyltransferases usually cannot utilize the bulky sulfonium-alkyl SAMs 
and protein engineering is required44-48. In addition, endogenous substrates should keep in a 
hypomethylated state for proper enzymatic labeling. A methyltransferase inhibitor, adenosine-
2’,3’-dialdehyde (Adox), was usually added to the cell culture medium to induce hypomethylated 
proteins44. However, Adox is a broad methyltransferases inhibitor which may affect normal 
cellular functions and cell growth. Moreover, hypomethylated substrates of irrelevant 
methyltransferases may also be labeled to some extent which would result in false positive results. 
Clustered regularly interspaced short palindromic repeats (CRISPR)-cas9 based gene KO system 
provides a new approach for inducing specific hypomethylated proteins.  
Finally, Jakobsson et al. described an HRMS-based substrate profiling approach for 
METTL13-N10. In this method, proteins were labelled using stable isotope labeling with amino 
acids in cell culture (SILAC) for better quantification, and the corresponding enzyme METTL13 
was knocked out10. Proteins obtained from normal and METTL13 KO cell lysates which contained 
the methylation sites were identified, quantified and compared10. As a result, Lys55 of eEF1A was 
identified as a new target site for METTL13-N and METTL13 was confirmed to be a dual 
methyltransferase10.   
Taken together, four methods including immunoprecipitation, peptide array, activity-based 
substrates labeling, and HRMS-based substrate profiling are reviewed. Immunoprecipitation is 
rapid, but it relies on high-quality antibodies. Peptide array is a high-throughput method but may 
not reflect the real situation of proteins. Activity-based substrate profiling provides a way to 
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directly label and enrich endogenous proteins, but it is time-consuming to design probes, 
synthesize probes and engineer proteins. HRMS-based method is straightforward, but it highly 
relies on expensive equipment and comprehensive MS data analysis.  
 1.4.3 Methylation readers 
To fully understand the functions of protein methylation, it is important to identify the “reader” 
proteins that determine the function of the methylation. The study of DNA and protein (especially 
histone) methylation readers uncovered their importance in epigenetic regulations. For example, 
Harris et al. reported that the binding of transcriptional anti-silencing factor (SUVH1 and SUVH3) 
to methylated DNA in Arabidopsis thaliana recruits DnaJ protein to enhance the expression of 
proximal genes51. Wysocka et al. reported that bromodomain and plant homeodomain (PHD) 
finger transcription factor (BPTF) specifically recognizes histone K4me3 and recruits the 
associated ATPase, SNF2L, to facilitate the transcription of chromatin52. Protein N-terminal 
methylation was reported to regulate protein-DNA. For example, trimethylated RCC1 enhanced 
its interaction with chromosome DNA and maintained normal mitosis5.  
Several motifs of histone lysine methylation readers have been confirmed including 
chromodomain, tudor domain, WD40-repeat domain, PHD domain, and acidic domain52-53. Wu et 
al. reported that histone K4me2/3 readers, NPM1, pp32, TaF1β, NCL and UBF, all harbored an 
acidic domain which mainly consisted of aspartic and glutamic acid residues53. Further, the acidic 
domain was confirmed to be necessary for their binding to histone K4me253. Moreover, 655 
proteins containing the acidic domain were predicted as putative histone K4me2 readers and 
protein MTERD2, Polr3gl and VHL were confirmed to bind to methylated histone K4 using pull-
down assay53. Taken together, histone methylation readers share common domains and it is a rapid 
approach to predict putative methylation readers by domain searching. 
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In addition to domain-based prediction, the most widely used approach to profile methylation 
reader is by co-IP. For example, protein SUVH1 and SUVH3 were identified as DNA methylation 
readers through co-immunoprecipitation with methylated double strand DNA oligonucleotides 
consisting a biotin affinity tag51.  BPTF was found as a binding partner of histone H3K4me3 
through co-IP with trimethylated histone H3 peptide52. 
As some of the interactions between reader proteins and the methylation sites are weak and 
transient, it would be difficult to capture those readers by direct co-immunoprecipitation. A photo-
affinity based protein pull-down method which enables covalently crosslinking has been applied 
in the profiling of histone methylation readers. Several photo-affinity probes containing a 
methylation marker, a photo reactive group and a report group have been designed and examples 
are shown in Fig. 1.6. Yang et al. demonstrated that probe 2 with a diazirine group (Fig. 1.6.A) is 
more efficient than probe 1 (Fig. 1.6.A) in labeling a known H3K4me3 reader, spindlin154. They 
explained that the bulky benzophenone group would block the binding site and disrupt the 
interaction between readers and H3K4me354. The mechanisms for radical generation via UV 
radiation are shown in Fig. 1.6.B. Both benzophenone and diazirine generate radicals under 
relatively longer UV wavelength (~ 350nm), which are good for in vitro and in vivo protein 
labeling. The photo excitation of benzophenone is reversible which gives good labeling yield by 
repeated excitation under UV radiation55. Unlike benzophenone, diazirine will release N2, which 
makes its photo excitation irreversible55. Compared to benzophenone, diazirine is chemically 
unstable as it isomerizes under light or by heating55. However, the small size of diazirine group 
makes it widely used in peptide-based photo affinity probes.  
Recently, Zhai et al. reported a self-assembled multivalent photo-affinity probe (Fig. 1.6.C) 
which exhibited high efficiency and specificity56. Methylated peptide and photo reactive group for 
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covalent crosslinking were immobilized on the surface of gold nanoparticles (AuNPs) which 
enabled purification of binding partners through one centrifugation step. Nonporous structure of 
AuNPs eliminated the non-specific bindings56. In addition, its multivalent property improved the 
crosslinking efficiency56. 
Although peptide-based photo affinity probes are easily synthesized and exhibit high labeling 
efficiency, they are often applied in cell lysates in vitro. Chin et al. reported a method to incorporate 
unnatural amino acid (UAA), p-benzoyl-L-phenylalanine (Fig. 1.6.D), to proteins synthesized in 
E. coli in vivo by selection of an aminoacyl-tRNA synthetase and tRNA which recognized one of 
the stop codons, TAG57. Incorporation of p-benzoyl-L-phenylalanine to proteins makes in vivo 






Figure 1.6 Photo active probes.  
(A) Photo affinity probes for histone H3K4me3 (probe1: benzophenone containing probe, 
probe2: diazirine containing probe)54. (B) Mechanisms for radical generation of benzophenone or 
diazirine containing probes55. (C) Self-assembled multivalent probe for histone H3K4me356. (D) 








Figure 1.7 Yeast three-hybrid system for screening of histone 3 K9me3 reader.  
(A) Histone3 N-terminal peptide fused to GAL4-binding domain (BD) (bait) recognizes and binds to the 
promoter of the reporter gene. H3K9 is methylated by SET domain of G9a and interacts with the prey 
protein which is fused to GAL4-activation domain (AD). The reconstitution of GAL4-BD and GAL4-AD 
activates the transcription of the downstream reporter gene. (B) The SET domain of G9a is not expressed 
in the system and the non-methylated H3K9 serves as a negative control which will not be recognized by 
the methylation reader and thus cannot reconstitute GAL4-BD and GAL4-AD. As a result, transcription of 
the downstream reporter gene is not activated58. 
 
The yeast two-hybrid (Y2H) system is a rapid and high-throughput approach for studying 
protein-protein interactions in vivo. It does not rely on expensive or sensitive equipment and does 
not need protein purifications or enrichments. In contrast, it is a genetic-based method for 
screening protein-protein interaction and its principle is shown in Fig. 1.758. Fields et al. firstly 
reported this novel genetic system for studying protein-protein interaction in 198959. The basic 
premise is that the activation domain (AD) and binding domain (BD) for most transcriptional 
factors (such as GAL4) are modular60. The AD activates gene transcription either through 
covalently fused to BD or stay proximity to BD by interacting with an intermediate protein59-61. 
The Y2H is a high-throughput method as it can screen protein-protein interaction with a gene 
library containing all the ORFs of an organism. Wieczorek et al. reported a yeast three-hybrid 
(Y3H) system for the screening of histone lysine methylation readers58. It is called three-hybrid as 
a third protein, histone lysine methyltransferase G9a (SET domain) which can modify the H3K9 
in vivo, is introduced to the system together with the bait and prey proteins58. Four previously 
confirmed H3K9me3 readers and 20 new putative readers were identified through Y3H58. It has to 
be noted that Y2/3H system with gene library screen often gives false positive and false negative 
results62, however, this rapid approach paves a cost-effective way for the rapid identification of 
protein methylation readers in vivo.  
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Considering the important roles of protein N-terminal methylation in cellular processes and 
little is known for their downstream signaling pathways, it is necessary to identify the N-terminal 
methylation readers. As a start point, immunoprecipitation, photo-affinity crosslinking and yeast 
three-hybrid system provide rapid and effective ways to screen new methylation readers. 
 1.4.4 Methylation erasers 
So far, two types of histone demethylases have been identified (Fig. 1.8). The first histone 
demethylase, nuclear polyamine oxidase (nPAO, LSD1, KDM1A, Fig. 1.8A) was discovered in 
2004, which is a flavin adenine dinucleotide (FAD) dependent monoamine oxidase and 
demethylates mono- and dimethylated lysine63. The second type of demethylases (Fig. 1.8B) are 
JmjC domain-containing histone demethylases. The first confirmed JmjC domain-containing 
histone demethylase is JHDM1 (KDM2) which is Fe(II) and α-ketoglutaric acid (AKG, 2OG) 




Figure 1.8 Two types of histone lysine demethylases.  
(A) FAD dependent histone demethylase63; (B) Fe(II) and α-ketoglutaric acid dependent histone 
demethylase63. 
 
Like protein methyltransferases, protein demethylases are enzymes and can be identified 
directly through activity-based assay. For example, Tsukada et al. developed an in vitro activity 
assay and successfully revealed JmjC domain-containing histone demethylase 1 (JHDM1) as a 
new histone demethylase64. Methyl-histone was labeled with 3H through histone 
methyltransferase-catalyzed methylation using 3H labeled SAM. Formaldehyde, the product of 
demethylation reaction, was converted into 3,5-diacethyl-1,4-dihydrolutidine for easier extraction 
and counting64. Ammonium iron(II) sulfate and α-ketoglutarate were supplemented in the 
demethylation buffer since they served as cofactors for previously identified DNA demethylase 
AlkB64-65. JHDM1 was identified as a demethylase by examining the demethylation activity from 
various HeLa cell lysate fractions64. 
Because protein demethylases are special methylation readers, the profiling methods for 
protein methylation readers can be applied to identify methylation erasers. Until now, none of the 
protein N-terminal demethylase was reported. Given that protein N-terminal methylation plays 
important functions in regulating mitosis and DNA damage repair, it is worthwhile to examine the 
existence of such erasers. 
 1.5 Purpose of this study 
Protein N-terminal methylation was discovered four decades ago, but little was known about 
its function. T h e  s t u d y  of RCC1 N-terminal methylation and the identification of NTMT1 as 
the corresponding enzyme uncovered its important function in regulating of DNA-protein 
interaction5, 29. Later, the identification of DDB2 as a new substrate for NTMT1 reveals a new 
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function of N-terminal methylation in regulating DNA damage repair14. NTMT1 was up- and 
down-regulated in colon and breast cancers, respectively26, 28. Dysregulation of NTMT1 was 
associated with developmental diseases and promotion of mammary oncogenesis26, 28. So far, the 
discovered N-terminal methylated proteins share a conserved N-terminal motif consisting of Met-
Xaa-Pro-Lys/Arg. Peptide-array based methylation assay indicates that protein with an expanded 
motif may also serve as NTMT1 substrates19. Here, we hypothesize that methylation of various 
NTMT1 substrates plays important roles in different types of cancers. However, only several 
proteins including RCC15, Retinoblastoma 15, protein SET5, DDB214, PARP315, CENP-A16, 
CENP-B and MYL9 are confirmed as NTMT1 substrates. It would be important and necessary to 
develop a method to uncover more of NTMT1 substrates. In this case, we developed an activity-
based approach to identify NTMT1 substrates from human cell lysates. We believe that some 
interesting and important substrates would be identified by this approach and it would  provide 
important information for elucidating the specific pathogenic mechanisms in NTMT1-associated 
tumorigenesis. 
 1.6 References 
1. Rice, J. C.; Allis, C. D. Histone methylation versus histone acetylation: new insights into 
epigenetic regulation. Curr. Opin. Cell Biol. 2001, 13 (3), 263-273. 
2. Allis, C. D.; Jenuwein, T. The molecular hallmarks of epigenetic control. Nat. Rev. 
Genet. 2016, 17 (8), 487-500. 
3. Wesche, J.; Kühn, S.; Kessler, B. M.; Salton, M.; Wolf, A. Protein arginine methylation: 
a prominent modification and its demethylation. Cell. Mol. Life Sci. 2017, 74 (18), 3305-
3315. 
4. Luo, M. Chemical and Biochemical Perspectives of Protein Lysine Methylation. Chem. 
Rev. 2018, 118 (14), 6656-6705. 
5. Tooley, C. E. S.; Petkowski, J. J.; Muratore-Schroeder, T. L.; Balsbaugh, J. L.; 
Shabanowitz, J.; Sabat, M.; Minor, W.; Hunt, D. F.; Macara, I. G. NRMT is an α-N-
methyltransferase that methylates RCC1 and retinoblastoma protein. Nature 2010, 466 
(7310), 1125-1128. 
27 
6. Webb, K. J.; Lipson, R. S.; Al-Hadid, Q.; Whitelegge, J. P.; Clarke, S. G. Identification 
of protein N-terminal methyltransferases in yeast and humans. Biochemistry 2010, 49 
(25), 5225-5235. 
7. Brosius, J.; Chen, R. The primary structure of protein L16 located at the 
peptidyltransferase center of Escherichia coli ribosomes. FEBS Lett. 1976, 68 (1), 105-
109. 
8. Wittmann-Liebold, B.; Pannenbecker, R. Primary structure of protein L33 from the large 
subunit of the Escherichia coli ribosome. FEBS Lett. 1976, 68 (1), 115-118. 
9. Petkowski, J. J.; Bonsignore, L. A.; Tooley, J. G.; Wilkey, D. W.; Merchant, M. L.; 
Macara, I. G.; Tooley, C. E. S. NRMT2 is an N-terminal monomethylase that primes for 
its homologue NRMT1. Biochem. J. 2013, 456 (3), 453-462. 
10. Jakobsson, M. E.; Małecki, J. M.; Halabelian, L.; Nilges, B. S.; Pinto, R.; Kudithipudi, 
S.; Munk, S.; Davydova, E.; Zuhairi, F. R.; Arrowsmith, C. H. The dual 
methyltransferase METTL13 targets N terminus and Lys55 of eEF1A and modulates 
codon-specific translation rates. Nat. Commun. 2018, 9 (1), 3411-3425. 
11. Patwardhan, P.; Miller, W. T. Processive phosphorylation: mechanism and biological 
importance. Cell. Signal. 2007, 19 (11), 2218-2226. 
12. Richardson, S. L.; Mao, Y.; Zhang, G.; Hanjra, P.; Peterson, D. L.; Huang, R. Kinetic 
mechanism of protein N-terminal methyltransferase 1. J. Biol. Chem. 2015, 290 (18), 
11601-11610. 
13. Dong, C.; Dong, G.; Li, L.; Zhu, L.; Tempel, W.; Liu, Y.; Huang, R.; Min, J. An 
asparagine/glycine switch governs product specificity of human N-terminal 
methyltransferase NTMT2. Commun. Biol. 2018, 1 (1), 183-191. 
14. Cai, Q.; Fu, L.; Wang, Z.; Gan, N.; Dai, X.; Wang, Y. α-N-methylation of damaged 
DNA-binding protein 2 (DDB2) and its function in nucleotide excision repair. J. Biol. 
Chem. 2014, 289 (23), 16046-16056. 
15. Dai, X.; Rulten, S. L.; You, C.; Caldecott, K. W.; Wang, Y. Identification and functional 
characterizations of N-terminal α-N-methylation and phosphorylation of serine 461 in 
human poly (ADP-ribose) polymerase 3. J. Proteome Res. 2015, 14 (6), 2575-2582. 
16. Sathyan, K. M.; Fachinetti, D.; Foltz, D. R. α-amino trimethylation of CENP-A by 
NRMT is required for full recruitment of the centromere. Nat. Commun. 2017, 8, 14678-
14692. 
17. Dai, X.; Otake, K.; You, C.; Cai, Q.; Wang, Z.; Masumoto, H.; Wang, Y. Identification 
of novel α-N-methylation of CENP-B that regulates its binding to the centromeric DNA. 
J. Proteome Res. 2013, 12 (9), 4167-4175. 
28 
18. Nevitt, C.; Tooley, J. G.; Tooley, C. E. S. N-terminal acetylation and methylation 
differentially affect the function of MYL9. Biochem. J. 2018, 475 (20), 3201-3219. 
19. Petkowski, J. J.; Schaner Tooley, C. E.; Anderson, L. C.; Shumilin, I. A.; Balsbaugh, J. 
L.; Shabanowitz, J.; Hunt, D. F.; Minor, W.; Macara, I. G. Substrate specificity of 
mammalian N-terminal α-amino methyltransferase NRMT. Biochemistry 2012, 51 (30), 
5942-5950. 
20. Hamey, J. J.; Winter, D. L.; Yagoub, D.; Overall, C. M.; Hart-Smith, G.; Wilkins, M. R. 
Novel N-terminal and lysine methyltransferases that target translation elongation factor 
1A in yeast and human. Mol. Cell. Proteomics 2016, 15 (1), 164-176. 
21. Villar-Garea, A.; Forne, I.; Vetter, I.; Kremmer, E.; Thomae, A.; Imhof, A. 
Developmental regulation of N-terminal H2B methylation in Drosophila melanogaster. 
Nucleic Acids Res. 2011, 40 (4), 1536-1549. 
22. Wu, R.; Yue, Y.; Zheng, X.; Li, H. Molecular basis for histone N-terminal methylation 
by NRMT1. Genes Dev. 2015, 29 (22), 2337-2342. 
23. Dong, C.; Mao, Y.; Tempel, W.; Qin, S.; Li, L.; Loppnau, P.; Huang, R.; Min, J. 
Structural basis for substrate recognition by the human N-terminal methyltransferase 1. 
Genes Dev. 2015, 29 (22), 2343-2348. 
24. https://www.proteinatlas.org/ENSG00000010165-METTL13/cell. 
25. Tooley, J. G.; Schaner Tooley, C. E. New roles for old modifications: Emerging roles of 
N‐terminal post‐translational modifications in development and disease. Protein Sci. 
2014, 23 (12), 1641-1649. 
26. Bonsignore, L. A.; Butler, J. S.; Klinge, C. M.; Tooley, C. E. S. Loss of the N-terminal 
methyltransferase NRMT1 increases sensitivity to DNA damage and promotes mammary 
oncogenesis. Oncotarget 2015, 6 (14), 12248-12263. 
27. Shields, K. M.; Tooley, J. G.; Petkowski, J. J.; Wilkey, D. W.; Garbett, N. C.; Merchant, 
M. L.; Cheng, A.; Schaner Tooley, C. E. Select human cancer mutants of NRMT1 alter 
its catalytic activity and decrease N‐terminal trimethylation. Protein Sci. 2017, 26 (8), 
1639-1652. 
28. Bonsignore, L. A.; Tooley, J. G.; Van Hoose, P. M.; Wang, E.; Cheng, A.; Cole, M. P.; 
Tooley, C. E. S. NRMT1 knockout mice exhibit phenotypes associated with impaired 
DNA repair and premature aging. Mech. Ageing Dev. 2015, 146, 42-52. 
29. Chen, T.; Muratore, T. L.; Schaner-Tooley, C. E.; Shabanowitz, J.; Hunt, D. F.; Macara, 
I. G. N-terminal α-methylation of RCC1 is necessary for stable chromatin association and 
normal mitosis. Nat. Cell Biol. 2007, 9 (5), 596-603. 
29 
30. Ibáñez, G.; McBean, J. L.; Astudillo, Y. M.; Luo, M. An enzyme-coupled ultrasensitive 
luminescence assay for protein methyltransferases. Anal. Biochem. 2010, 401 (2), 203-
210. 
31. Kimura, S.; Miyauchi, K.; Ikeuchi, Y.; Thiaville, P. C.; Crécy-Lagard, V. d.; Suzuki, T. 
Discovery of the β-barrel–type RNA methyltransferase responsible for N 6-methylation 
of N 6-threonylcarbamoyladenosine in tRNAs. Nucleic Acids Res. 2014, 42 (14), 9350-
9365. 
32. Jackman, J. E.; Montange, R. K.; Malik, H. S.; Phizicky, E. M. Identification of the yeast 
gene encoding the tRNA m1G methyltransferase responsible for modification at position 
9. Rna 2003, 9 (5), 574-585. 
33. Martzen, M. R.; McCraith, S. M.; Spinelli, S. L.; Torres, F. M.; Fields, S.; Grayhack, E. 
J.; Phizicky, E. M. A biochemical genomics approach for identifying genes by the 
activity of their products. Science 1999, 286 (5442), 1153-1155. 
34. Green, N. M. Avidin. Adv. Protein Chem.1975, 29, 85-133. 
35. Katz, J. E.; Dlakić, M.; Clarke, S. Automated identification of putative 
methyltransferases from genomic open reading frames. Mol. Cell. Proteomics 2003, 2 
(8), 525-540. 
36. Boisvert, F.-M.; Côté, J.; Boulanger, M.-C.; Richard, S. A proteomic analysis of arginine-
methylated protein complexes. Mol. Cell. Proteomics 2003, 2 (12), 1319-1330. 
37. Frank, R. The SPOT-synthesis technique: synthetic peptide arrays on membrane 
supports—principles and applications. J. Immunol. Methods 2002, 267 (1), 13-26. 
38. Frank, R.; Döring, R. Simultaneous multiple peptide synthesis under continuous flow 
conditions on cellulose paper discs as segmental solid supports. Tetrahedron 1988, 44 
(19), 6031-6040. 
39. Najbauer, J.; Johnson, B. A.; Young, A. L.; Aswad, D. Peptides with sequences similar to 
glycine, arginine-rich motifs in proteins interacting with RNA are efficiently recognized 
by methyltransferase (s) modifying arginine in numerous proteins. J. Biol. Chem. 1993, 
268 (14), 10501-10509. 
40. Wooderchak, W. L.; Zang, T.; Zhou, Z. S.; Acuna, M.; Tahara, S. M.; Hevel, J. M. 
Substrate profiling of PRMT1 reveals amino acid sequences that extend beyond the 
“RGG” paradigm. Biochemistry 2008, 47 (36), 9456-9466. 
41. Dhayalan, A.; Kudithipudi, S.; Rathert, P.; Jeltsch, A. Specificity analysis-based 
identification of new methylation targets of the SET7/9 protein lysine methyltransferase. 
Chem. Biol. 2011, 18 (1), 111-120. 
30 
42. Pljevaljcic, G.; Pignot, M.; Weinhold, E. Design of a new fluorescent cofactor for DNA 
methyltransferases and sequence-specific labeling of DNA. J. Am. Chem. Soc. 2003, 125 
(12), 3486-3492. 
43. Klimašauskas, S.; Weinhold, E. A new tool for biotechnology: AdoMet-dependent 
methyltransferases. Trends Biotechnol. 2007, 25 (3), 99-104. 
44. Guo, H.; Wang, R.; Zheng, W.; Chen, Y.; Blum, G.; Deng, H.; Luo, M. Profiling 
substrates of protein arginine N-methyltransferase 3 with S-adenosyl-L-methionine 
analogues. ACS Chem. Biol. 2013, 9 (2), 476-484. 
45. Wang, R.; Zheng, W.; Yu, H.; Deng, H.; Luo, M. Labeling substrates of protein arginine 
methyltransferase with engineered enzymes and matched S-adenosyl-L-methionine 
analogues. J. Am. Chem. Soc. 2011, 133 (20), 7648-7651. 
46. Islam, K.; Chen, Y.; Wu, H.; Bothwell, I. R.; Blum, G. J.; Zeng, H.; Dong, A.; Zheng, 
W.; Min, J.; Deng, H. Defining efficient enzyme–cofactor pairs for bioorthogonal 
profiling of protein methylation. P. Natl. Acad. Sci. USA 2013, 110 (42), 16778-16783. 
47. Blum, G.; Islam, K.; Luo, M. Using azido analogue of S-Adenosyl-L-methionine for 
Bioorthogonal Profiling of Protein Methylation (BPPM). Curr. Protoc. Chem. Biol. 2013, 
5, 45-66. 
48. Dalhoff, C.; Lukinavičius, G.; Klimašauskas, S.; Weinhold, E. Synthesis of S-adenosyl-
L-methionine analogs and their use for sequence-specific transalkylation of DNA by 
methyltransferases. Nat. Protoc. 2006, 1 (4), 1879-1886. 
49. Rostovtsev, V. V.; Green, L. G.; Fokin, V. V.; Sharpless, K. B. A stepwise huisgen 
cycloaddition process: copper (I)‐catalyzed regioselective “ligation” of azides and 
terminal alkynes. Angew. Chem., Int. Ed. 2002, 41 (14), 2596-2599. 
50. Tornøe, C. W.; Christensen, C.; Meldal, M. Peptidotriazoles on solid phase:[1, 2, 3]-
triazoles by regiospecific copper (I)-catalyzed 1, 3-dipolar cycloadditions of terminal 
alkynes to azides. J. Org. Chem. 2002, 67 (9), 3057-3064. 
51. Harris, C. J.; Scheibe, M.; Wongpalee, S. P.; Liu, W.; Cornett, E. M.; Vaughan, R. M.; 
Li, X.; Chen, W.; Xue, Y.; Zhong, Z. A DNA methylation reader complex that enhances 
gene transcription. Science 2018, 362 (6419), 1182-1186. 
52. Wysocka, J.; Swigut, T.; Xiao, H.; Milne, T. A.; Kwon, S. Y.; Landry, J.; Kauer, M.; 
Tackett, A. J.; Chait, B. T.; Badenhorst, P. A PHD finger of NURF couples histone H3 
lysine 4 trimethylation with chromatin remodelling. Nature 2006, 442 (7098), 86-90. 
53. Wu, M.; Wei, W.; Chen, J.; Cong, R.; Shi, T.; Li, J.; Wong, J.; Du, J. X. Acidic domains 
differentially read histone H3 lysine 4 methylation status and are widely present in 
chromatin-associated proteins. Sci. China Life Sci. 2017, 60 (2), 138-151. 
31 
54. Yang, T.; Liu, Z.; Li, X. D. Developing diazirine-based chemical probes to identify 
histone modification ‘readers’ and ‘erasers’. Chem. Sci. 2015, 6 (2), 1011-1017. 
55. Murale, D. P.; Hong, S. C.; Haque, M. M.; Lee, J.-S. Photo-affinity labeling (PAL) in 
chemical proteomics: a handy tool to investigate protein-protein interactions (PPIs). 
Proteome Sci. 2016, 15 (1), 14-47. 
56. Zhai, G.; Dong, H.; Guo, Z.; Feng, W.; Jin, J.; Zhang, T.; Chen, C.; Chen, P.; Tian, S.; 
Bai, X. An Efficient Approach for Selective Enrichment of Histone Modification Readers 
Using Self-Assembled Multivalent Photoaffinity Peptide Probes. Anal. Chem. 2018, 90 
(19), 11385-11392. 
57. Chin, J. W.; Martin, A. B.; King, D. S.; Wang, L.; Schultz, P. G. Addition of a 
photocrosslinking amino acid to the genetic code of Escherichia coli. P. Natl. Acad. Sci. 
USA 2002, 99 (17), 11020-11024. 
58. Rawłuszko-Wieczorek, A. A.; Knodel, F.; Tamas, R.; Dhayalan, A.; Jeltsch, A. 
Identification of protein lysine methylation readers with a yeast three-hybrid approach. 
Epigenet. Chromatin 2018, 11 (1), 4-15. 
59. Fields, S.; Song, O. A novel genetic system to detect protein–protein interactions. Nature 
1989, 340 (6230), 245-246. 
60. Frankel, A. D.; Kim, P. S. Modular structure of transcription factors: implications for 
gene regulation. Cell 1991, 65 (5), 717-719. 
61. Liu, F.; Green, M. R. A specific member of the ATF transcription factor family can 
mediate transcription activation by the adenovirus E1a protein. Cell 1990, 61 (7), 1217-
1224. 
62. Brückner, A.; Polge, C.; Lentze, N.; Auerbach, D.; Schlattner, U. Yeast two-hybrid, a 
powerful tool for systems biology. Int. J. Mol. Sci. 2009, 10 (6), 2763-2788. 
63. Shi, Y. G.; Tsukada, Y. The discovery of histone demethylases. CSH Perspect Biol. 
2013, 5 (9), a017947. 
64. Tsukada, Y.-i.; Fang, J.; Erdjument-Bromage, H.; Warren, M. E.; Borchers, C. H.; 
Tempst, P.; Zhang, Y. Histone demethylation by a family of JmjC domain-containing 
proteins. Nature 2006, 439 (7078), 811-816. 
65. Falnes, P. Ø.; Johansen, R. F.; Seeberg, E. AlkB-mediated oxidative demethylation 
reverses DNA damage in Escherichia coli. Nature 2002, 419 (6903), 178-182. 
 
32 
Chapter 2 - Activity-based substrate profiling of NTMT1 
 2.1 Introduction 
Methylation is a common modification for small bioactive molecules and biomacromolecules 
among all kinds of organisms. In woody poplar plants, methylation of caffeoyl coenzyme A by 
caffeoyl coenzyme A O-methyltransferase (CCoAOMT) is essential in lignin biosynthesis1. In 
human body, many essential endogenous chemicals including trace amines (e.g., 3-
methoxytyramine, N-methyltyramine, N-methylphenethylamine)2 and hormones (e.g., adrenaline) 
are methylated by certain methyltransferases. Methylation of biomacromolecules (e.g., DNA, 
histone) by relevant methyltransferases (e.g., DNA methyltransferases, histone lysine 
methyltransferases, histone arginine methyltransferases) have been deeply studied due to their 
important functions in epigenetics. For example, trimethylation of histone 3 lysine 4 is associated 
with gene activation, while dimethylation of histone 3 lysine 9 is related to the silence of gene 
expression3. In last decade, three human protein N-terminal methyltransferases (NTMT1, NTMT2, 
and METTL13) were discovered, which greatly promoted the study of protein N-terminal 
methylation. 
Protein N-terminal methylation has been demonstrated to regulate DNA-protein interaction 
and DNA damage repair4-5. N-terminal trimethylation of RCC1 and CENP-B enhances their 
binding with chromosome DNA4, 6. N-terminal methylation of DDB2 promotes its nucleus 
localization5. Dysregulation of NTMT1 has been implicated in severe diseases such as cancer. 
NTMT1 functions as a tumor suppressor in breast cancer but additional study indicates that it may 
act as an oncogene in colorectal cancer7-8.  
So far, the identified NTMT1 substrates including RCC1, DDB2, PARP3, CENP-A, CENP-B, 
SET and retinoblastoma 1, contain an N-terminal Met-Xaa-Pro-Lys/Arg motif5-6, 9-11. Peptide-
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based methylation assay indicated that a protein with an expanded motif (Met-Xaa-Xaa-Lys/Arg) 
may also serve as a substrate for NTMT112. However, peptides only contain very short amino acid 
sequences and usually do not have a tertiary structure, and therefore, methylation assay on peptide 
and protein level may not be consistent to each other. Considering the important roles of N-
terminal methylation in cellular processes and human diseases, it would be necessary to develop a 
substrate profiling method for NTMT1. 
Activity-based substrate profiling assay has been successfully applied to the study of DNA and 
protein methylation. It is a powerful tool to label endogenous proteins via enzyme catalyzed 
reactions in physiological condition. Specifically, several sulfonium-alkyl SAM analogs have been 
reported for substrate profiling of DNA and protein methyltransferases13-15. The sulfonium-alkyl 
SAMs contain either an alkynyl or an azide group to incorporate an affinity tag (e.g., biotin) to the 
substrates utilizing the efficient click chemistry13-15. In most situations, the wild type protein 
methyltransferases are not able to transfer the bulky alkyl groups to their targets and thus the time-
consuming protein engineering is required13-15. Here, we found that one of the reported SAM 
analogs13-15, Hey-SAM, could be taken by wt NTMT1 as cofactor. Moreover, NTMT1 KO cell 
line was generated to produce hypomethylated NTMT1 substrates, which avoided the use of Adox, 
an inhibitor for SAM dependent methyltransferases, and overcame the drawbacks of adding Adox 
to cell culture. 
 2.2 Results and discussion 
 2.2.1 Plasmid construction and purification of NTMT1 
To express protein NTMT1 in E. coli, plasmid pET28-MHL-NTMT1 containing an N-terminal 
His6-tag with a TEV digestion site was constructed (Fig. 2.1A & Fig.2.1B). Protein His6-NTMT1 




Figure 2.1 Plasmid construction and purification of NTMT1.  
(A) PCR products of NTMT1; (B) Digestion of pET28-MHL and PCR products with NdeI and HindIII; 
(C) SDS-PAGE of purified NTMT1. 
 
 2.2.2 Synthesis of Hey-SAM as a SAM surrogate 
To perform the activity-based substrate profiling, the natural cofactor SAM was modified to 
contain a terminal alkynyl for introducing a reporter group by click chemistry. Many SAM analogs 
have been reported for profiling substrates of PKMTs and PRMTs13-15. Most of the surrogates 
cannot be directly utilized by wt PRMTs or PKMTs due to their bulky sizes but can serve as 
cofactors for certain mutants13-15. NTMT1 crystal structures (Fig. 2.2A) indicate that SAH is 
deeply buried in a big pocket which may be able to accommodate a bulky SAM surrogate. Among 
all the reported SAM analogs, (E)-hex-2-en-5-ynyl-SAM (Hey-SAM, Fig. 2.2.B), is especially 
useful, which features a sulfonium-β-sp2 carbon in addition to a terminal alkyne in its structure15. 
An SN2 reaction mechanism has been proposed as a common mechanism for SAM dependent 
methylation16. For sulfonium-alkyl SAM analog, the substitution of one hydrogen from the 
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reactive methyl with an alkyl group destabilizes the transition state and slows down the reaction, 
which can be rescued by placing a double or triple bond to the adjacent carbon17. The driving force 
for the accelerated rate is the electronic conjugation between the π-orbital and the newly formed 
p-orbital which stabilizes the transition state17. 
Hey-SAM was synthesized by Dr. Gaochao Huang in our lab using a modified synthetic route, 
which will be published somewhere else. Through the new synthetic route (Fig. 2.2B), SAH was 
converted into Hey-SAM almost quantitatively. Hey-SAM was characterized and confirmed by 
1H NMR (Appendix A), COSY (Appendix A), 13C NMR (Appendix A), HPLC (Fig. 2.2C) and 




Figure 2.2 Synthesis of Hey-SAM as a SAM surrogate. 
(A) Surface model of substrate binding with NTMT1 (PDB: 5E1B). The sulfur atom of SAH is shown in 
yellow. Peptide SPKRIA is shown in blue. Protein surface is represented in grey. (B) Scheme for Hey-SAM 
synthesis. (C) HPLC analysis of Hey-SAM (elution condition: 0.01% TFA in water). (D) LC-MS analysis 
of Hey-SAM (calculated [M]+: 463.1758; detected: 463.1776). 
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 2.2.3 Alkylation of RCC1 peptide with Hey-SAM and wt NTMT1 
To investigate whether wt NTMT1 would utilize Hey-SAM as its cofactor, a peptide (N-
terminal analog of RCC1, Fig. 2.3A) containing the first ten N-terminal residues (excluding the 
initial methionine) of RCC1 was synthesized and used as the substrate. As a control, RCC1 peptide 
was mixed with the natural cofactor SAM with or without wt NTMT1, and mass spectrometry 
analysis showed that RCC1 peptide was di- and trimethylated only in the presence of wt NTMT1 
(Fig. 2.3B & Fig. 2.3C). For the trimethylated product, the loss of a formaldehyde (~ 30 Dalton 
mass shift) was detected which was also observed in other reported peptides18-19. The alkylation 
reaction between RCC1 peptide and Hey-SAM catalyzed by wt NTMT1 was confirmed by mass 
spectrometry (Fig. 2.3E). In contrast to SAM, with which di- and trimethylated products were 
observed, only monoalkylated peptide was formed with Hey-SAM and this may be due to the 
bulky size of the Hey group which prevents multiple alkylation. The monoalkylation was 
confirmed to be enzyme-catalyzed as no alkylated products were detected in the absence of wt 






Figure 2.3 MS analysis of RCC1 peptide methylation and alkylation by wt hNTMT1 using 
different cofactors.  
All reactions were carried out with 20 µM RCC1 peptide and 200 µM cofactors for 2h at 37 ℃. (A) Mass 
spectrum and HPLC analysis (inset) of the synthesized RCC1 peptide (calculated [M + H]+: 1197.7656; 
detected: 1197.7715). (B) Mass spectrum of RCC1 peptide mixed with SAM in the absence of wt NTMT1 
(calculated [M + H]+: 1197.7656; detected: 1197.7689). (C) Mass spectrum of RCC1 peptide methylation 
in the presence of SAM and wt NTMT1 (calculated [M + 2CH3 + H]+: 1225.7969, [M + 2CH3 + Na]+: 
1247.7789, [M + 3CH3 - HCHO]+: 1209.8020; detected: 1225.7980, 1247.7787, and 1209.7994). (D) Mass 
spectrum of RCC1 peptide mixed with Hey-SAM in the absence of wt NTMT1 (calculated [M + H]+: 
1197.7656; detected: 1197.7690). (E) Mass spectrum of RCC1 peptide alkylation in the presence of Hey-
SAM and wt NTMT1 (calculated [M + Hey + H]+: 1275.8126; detected: 1275.8153). 
 
 2.2.4 Alkylation of RCC1 protein with Hey-SAM and wt NTMT1  
Because RCC1 peptide can be alkylated with Hey-SAM and wt NTMT1, next we examined 
whether RCC1 protein would be alkylated as well. To do this, RCC1 protein with a C-terminal 
His6-tag was expressed in E. coli and purified by Ni-NTA affinity chromatography (Fig. 2.4B). As 
the initial methionine removal is a common modification in E. coli4, 20-21, RCC1 purified from E. 
coli was subject to intact protein mass spectrometry to verify whether its initial methionine was 
removed. Here, we found three forms of RCC1 purified from E. coli Bl21 (DE3) strain (Fig. 2.4A): 
full length (RCC1), initial methionine removed (RCC1 - M), and methionine and serine removed 
(RCC1 - MS). The full length RCC1 and RCC1 - MS were not the correct substrates of NTMT14. 
To enhance the yield of the correct substrate, RCC1-M, the protein was expressed in a mutant E. 
coli BL21 (DE3) strain, C41 (DE3) (Fig. 2.4C), which is often used to express toxic proteins. The 
majority proteins purified from C41 (DE3) were full length and methionine removed RCC1. Thus, 
we decided to choose C41 (DE3) strain to express the RCC1. When RCC1 was incubated with 
SAM and wt NTMT1, mono- and dimethylated RCC1 products were detected by intact protein 
mass (Fig. 2.4E). Similar to the result of RCC1 peptide, only monoalkylated RCC1 (Fig. 2.4G) 
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was observed after incubating with Hey-SAM and wt NTMT1. RCC1 methylation and alkylation 
were enzyme-catalyzed because no products were observed in the absence of wt NTMT1 (Fig. 
2.4D & Fig. 2.4F). In addition, the modification site of RCC1 was confirmed to be the N-terminus 
using in-gel trypsin digestion and subsequent analysis with UPLC-HRMS (Fig. 2.4H). All these 





Figure 2.4 MS analysis of RCC1 protein methylation and alkylation by wt hNTMT1 using 
different cofactors.  
All reactions were carried out with 20 µM RCC1 protein and 200 µM cofactors at 37℃. The molecular 
weight (MW) of full length RCC1-His6 is 46034.14 D; the MW of methionine removed RCC1-His6 (RCC1 
- M) is 45902.95 D; the MW of methionine and serine removed RCC1-His6 (RCC1 - MS) is 45815.87 D. 
(A) Intact protein mass of RCC1 purified from E. coli BL21(DE3) strain. (B) SDS-PAGE of RCC1 protein. 
(C) Intact protein mass of RCC1 purified from E. coli C41(DE3) strain. (D) Intact protein mass of RCC1 
mixed with SAM. (E) Intact protein mass of RCC1 mixed with SAM and wt NTMT1. (F) Intact protein 
mass of RCC1 mixed with Hey-SAM. (G) Intact protein mass of RCC1 mixed with Hey-SAM and wt 
NTMT1. (H) MSE spectrum of mapping the modification site on RCC1 protein. 
 
 2.2.5 Thermodynamic and kinetic analysis of wt NTMT1 with Hey-SAM and RCC1 
peptide 
To compare the binding affinities of SAM/Hey-SAM with wt hNTMT1, isothermal titration 
calorimetry (ITC) experiment was performed. ITC was commonly used to determine the 
thermodynamic parameters of protein-protein interaction and protein-small molecule interaction 
in solution. Petkowski et al. and Dong et al. have applied ITC to study the binding affinities of 
NTMT1 with peptide substrates12, 22. The titration curves are shown in Fig 2.5 and the 
thermodynamic parameters including dissociation constants (Kd), binding stoichiometries (N), 
enthalpy changes (ΔH) and entropy changes (ΔS) are summarized in Table 2.1. SAM and Hey-
SAM displayed similar dissociation constants (Kd) and stoichiometries (N), indicating that both 
have similar binding modes with wt NTMT1. The stoichiometries of NTMT1 with the cofactors 
or peptide substrate are less than 1 (~ 0.4 - 0.6), suggesting that only half of the enzyme’s active 
sites were occupied with its substrates. NTMT1 purified from E. coli will bind with some 
endogenous SAM/SAH22, which may contribute to the small N value.  
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Table 2.1 Thermodynamic parameters of wt NTMT1 with cofactors and RCC1 peptide. 
 Kd (μM) N ΔH (kcal/mol) ΔS (cal/(mol·℃)) 
SAM 1.43 ± 0.325 0.393 ± 0.022  -17.40 ± 0.775 -31.55 ± 3.05 
Hey-SAM 1.29 ± 0.165  0.382 ± 0.039 -13.71 ± 1.59 -19 ± 5.1 
RCC1 peptide 1.22 ± 0.019 0.63 ± 0.072 -10.95 ± 0.27 -9.65 ± 0.855 
 
 
Figure 2.5 Affinity measurements of wt NTMT1 with cofactors and RCC1 peptide by ITC.  
(A) Titration curve for SAM. (B) Titration curve for Hey-SAM. (C) Titration curve for RCC1 peptide. 
 
To evaluate and compare the reaction rates of cofactor SAM and Hey-SAM, their kinetic 
parameters were studied with RCC1 peptide and wt hNTMT1. To measure the reaction rate, SAH 
release (retention time: 5.2 min, Fig 2.6A & Fig 2.6B) was monitored and quantified by HPLC 
with adenosine (retention time: 6.8 min, Fig 2.6A & Fig 2.6B) as an external standard. The initial 
reaction rates and concentrations of substrates were fitted to Michaelis-Menten curve (Fig. 2.6C 
& Fig. 2.6D). The turnover numbers (kcat) and Michaelis constants (KM) are shown in Table 2.2.  
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Table 2.2 Kinetic parameters of wt NTMT1 with RCC1 peptide and cofactors. 
 KM (μM) kcat (min
-1) 
SAM 0.38 ± 0.029 0.45 ± 0.008 
Hey-SAM 1.40 ± 0.085 0.4 ± 0.006 
RCC1 peptide 1.96 ± 0.236 /SAM 0.58 ± 0.022 /SAM 
2.09 ± 0.176 /Hey-SAM 0.52 ± 0.014 /Hey-SAM 
 
 
The kcat values of SAM and Hey-SAM were determined to be similar when NTMT1 was 
saturated with the RCC1 peptide. However, the KM of Hey-SAM was ~ 4-times higher than that 
of SAM, indicating that NTMT1 displays a higher affinity with its native cofactor SAM than with 
Hey-SAM. Consequently, the catalytic efficiency (kcat/KM) of SAM (1.97  10
4 M−1s−1) was ~ 4-
times higher than that of Hey-SAM (4.76  103 M−1s−1). The KM and kcat values of RCC1 peptide 
in the presence of saturated cofactors were very close, suggesting that the cofactors have marginal 
effects on the binding affinity and turnover of the wt NTMT1 with the peptide substrate.       
Taken together, thermodynamic and kinetic studies suggest that Hey-SAM is a good SAM 
surrogate for wt NTMT1 and can be applied to label substrates with a terminal alkynyl which can 




Figure 2.6 Kinetic study of wt NTMT1 with RCC1 peptide and cofactors.  
(A) Monitoring SAH release by HPLC for the reaction between 20 µM SAM and 4 µM RCC1 peptide in 
the presence of 0.3 µM wt NTMT1. (B) Monitoring SAH release by HPLC for the reaction between 20 µM 
Hey-SAM and 8 µM RCC1 peptide in the presence of 0.3 µM wt NTMT1. (C) Determination of kinetic 
parameters of cofactor SAM (red) and Hey-SAM (black) in the presence of RCC1 peptide and 0.3 µM wt 
NTMT1. (D) Determination of kinetic parameters of RCC1 peptide with SAM (red) or Hey-SAM (black) 




 2.2.6 Labeling of RCC1 protein with biotin via click chemistry 
To determine whether Cu(I) catalyzed click chemistry would work, RCC1 peptide was 
incubated with Hey-SAM and wt NTMT1 for 2h followed by addition of diazo biotin azide (DBA) 
in the presence of CuSO4, tris(benzyltriazolylmethyl)amine (TBTA) and tris(2-
carboxyethyl)phosphine hydrochloride (TCEP)23-24. As expected, LC-MS analysis (Fig. 2.7A) 
showed that RCC1 was successfully labeled with a biotin group.  
To examine whether RCC1 protein would be labeled with a biotin, RCC1 protein was alkylated 
with Hey-SAM and wt NTMT1, reacted with DBA by Cu(I) catalyzed click chemistry and checked 
by western blot (WB) with streptavidin-HRP (Fig. 2.7B). Negative controls were performed either 
in the absence of NTMT1 or using SAM to substitute Hey-SAM (Fig. 2.7B). The attachment of 
biotin was only detected for the alkylated RCC1 with Hey-SAM and NTMT1 (Fig. 2.7B). Negative 
controls contained similar loading amount of RCC1, but no biotin signal was detected with 
streptavidin (SA)-HRP (Fig. 2.7B). Moreover, to confirm that biotin was attached on the N-
terminus of RCC1, the SA-based gel shift assay followed by in-gel digestion and LC-MS analysis 
were performed (Fig. 2.7B). As previously demonstrated, only partial of recombinant RCC1 
protein purified from E. coli was the active substrate for NTMT1 and gel shift assay was used to 
enrich the biotin labeled RCC1. To perform gel shift assay, properly alkylated and biotin labeled 
protein samples were denatured and mixed with native SA before loading to SDS-PAGE. As 
shown in Fig 2.7B, lane 3 represents protein SA which exists as a mixture of dimer (26.4 kDa) and 
tetramer (52.8 kDa). Two new bands were specifically formed in lane 9 (Fig 2.7B) and were 
speculated as RCC1 + 2SA (72 kDa) and 2RCC1 + 4SA (144 kDa) according to their molecular 
weights on SDS-PAGE. The newly formed bands were excised, digested with trypsin and analyzed 
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by LC-MS. The biotin labeled N-terminal SPK peptide was detected with a retention time of 24.8 




Figure 2.7 RCC1 peptide and protein were labeled with a biotin tag by Hey-SAM and click 
chemistry.  
(A) Mass spectrum of biotin labelled RCC1 peptide (calculated [M + H]+: 1987.1288, detected: 1987.1287). 
(B) Streptavidin gel shift assay. Lane 2 represents purified RCC1. lane 3 represents purified NTMT1. Lanes 
4-6 represent RCC1 sequentially labeled with cofactors and DBA by click chemistry. Lanes 7-8 represent 
gel shift assay with non-denatured SA. Lanes 4-6 were detected by western blot with rabbit anti-hRCC1 
antibody and streptavidin-HRP, respectively. (C) MSE spectrum of mapping the biotin tag to N-terminal 
serine (calculated precursor ion [M + H]+: 1120.5608; detected: 1120.5615).  
 2.2.7 Labeling overexpressed RCC1 protein with biotin by Hey-SAM and click 
chemistry in E. coli lysates 
As a proof of concept, the activity-based substrate profiling method was applied to a complex 
mixture, the E. coli cell lysates. Similar to the above procedure for purified RCC1 protein, the E. 
coli lysates containing overexpressed RCC1 were employed as substrates for NTMT1, methylated 
or alkylated with SAM or Hey-SAM, and reacted with DBA via Cu(I) catalyzed click chemistry. 
As expected, only the properly alkylated and biotin labeled RCC1 (~ 46 kDa) was successfully 
enriched and purified by streptavidin beads (Lane 9 in Fig. 2.8A & Fig. 2.8B). According to the 
results shown in SDS-PAGE (Fig 2.8A) and western blot (Fig. 2.8B), control samples either treated 
with SAM or in the absence of NTMT1 failed to enrich RCC1 though the loading volumes were 
the same. The purified RCC1 was further quantified by WB (Fig. 2.8C), in which 12 ng, 16 ng, 24 
ng and 36 ng of purified RCC1 proteins were loaded as reference. Considering that the amount of 
active RCC1 substrate purified from E. coli varied between 30% and 50% of the total protein, 
quantification of the purified RCC1 by western blot gave a normalized recovery yield of 8%-13%, 





Figure 2.8 Labeling of RCC1 in E. coli lysates with a biotin tag via activity-based substrate 
profiling strategy.  
(A) Overexpressed RCC1 protein in E. coli lysates was biotin labeled and enriched by streptavidin beads. 
(B) Proteins enriched and purified by streptavidin beads were detected by WB using rabbit anti-RCC1 
antibody. (C) Quantification of purified RCC1 by WB (Input: before incubating with streptavidin beads; 
Pull down: proteins enriched and purified using streptavidin beads). 
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 2.2.8 Knockout of NTMT1 in HEK293FT  
Inducing of methyl-accepting proteins in a hypomethylated state is one important premise for 
the activity-based substrate profiling strategy. Previous protocols rely on methyltransferase 
inhibitors to generate hypomethylated proteins25. One of the most commonly used inhibitors, 
Adox, were broadly applied to induce hypomethylated proteins in human cell lines14, 24-26. Adox, 
a cell permeable inhibitor of SAH hydrolase, results in the accumulation of intracellular SAH level 
and therefore inhibits the catalytic activity of methyltransferases. Though Adox was used as a 
broad inhibitor for all methyltransferases, several studies demonstrated that DNA 
methyltransferases were less sensitive to its treatment compared to protein methyltransferases27-28. 
The typical concentrations of Adox supplemented in culture medium were 15-20 μM29-30 because 
a higher concentration would cause cell apoptosis31. In addition, only a small fraction of protein 
methyltransferases in cells would be inhibited by Adox because Adox only works on the newly 
translated proteins after its treatment25. Though Adox exhibits less inhibition effects for DNA 
methylation, it can inhibit histone lysine methyltransferases32 and therefore may affect the 
regulation of epigenetics. 
Considering that Adox is a very broad but not a specific protein methylation inhibitor and many 
of its adverse effects, we decided to specifically induce NTMT1 substrates to a hypomethylated 
state by generating NTMT1 gene knockout cell line. Ran et al. reported a protocol for genome 
editing using CRISPR-Cas9 system33. The principle for CRISPR-Cas9 based genome editing is 
that Cas9 nuclease targets the site of genome DNA which precedes a protospacer adjacent motif 
(PAM) by a single-guide RNA (sgRNA) consisting of 20 nucleotides complementary with the 
target DNA sequence33. Specifically, the PAM sequence for Streptococcus pyogenes Cas9 
(SpCas9) is NGG33. The cleaved double strands DNA by cas9 can be repaired via “nonhomologous 
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end joining (NHEJ)” or “homology-directed repair (HDR)” in human cells, resulting in nucleotides 
deletion or addition which eventually may introduce a stop codon or alter the primary sequences 
of the target protein33. 
As human embryonic kidney (HEK) 293FT cells are easily cultured and their transfection 
efficiency is usually high, we decided to knock out NTMT1 in HEK293FT cells. To do this, 
primers containing the 20 nucleotides complementary to the target DNA sequences were 
synthesized, annealed and inserted into the digested vector PX459 which contains the coding 
sequences of SpCas9 and puromycin selection marker.  Newly constructed plasmids containing 
the guide sequences were transfected into HEK293FT cells. After puromycin selection, most of 
the cells died and the survived ones were diluted and seeded into 96-well plates for single cell 
screening. After two weeks, the cells derived from one single cell were transferred into 24-well 




Figure 2.9 Construction of NTMT1 KO cell line.  
(A) Detection of NTMT1 expression by WB using anti-NTMT1 antibody in normal HEK293FT and 
NTMT1 KO cells. (B) Detection the expression of actin as a loading control by WB using anti-actin 
antibody in normal HEK293FT and NTMT1 KO cells. (C) DNA gel for amplification of NTMT1 exon1 
from normal HEK293FT and NTMT1 gene KO cells. (D) DNA sequencing chromatogram of NTMT1 
exon1 amplified from NTMT1 gene KO cells. (E) Alignment of NTMT1 exon1 from NCBI, normal 
HEK293FT and NTMT1 KO cells (KO45 represents HEK293FT NTMT1 gene knockout cell #45). (F) 
Alignment of translated NTMT1 amino acid sequences from NCBI, normal HEK293FT and NTMT1 gene 
KO cells. 
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The rabbit anti-NTMT1 antibody is sensitive to detect endogenous NTMT1 (~ 25 kDa, Fig. 
2.9A) from normal HEK293FT cells though a nonspecific band (~ 45 kDa) was also detected. 
Using actin as a protein loading control (Fig. 2.9B), the absence of NTMT1 shown in WB (Fig. 
2.9B) indicated that NTMT1 was successfully knocked out. Further, the gene locus from normal 
and NTMT1 gene KO HEK293FT cells were extracted with Tissue DNA Kit, amplified by PCR 
and sequenced. Both DNA electrophoresis (Fig. 2.9C) and sequencing (Fig. 2.9D) results 
confirmed the deletion of ~ 70 nucleotides (Fig. 2.9C, 2.9D & 2.9E) and insertion of a stop codon 
(Fig. 2.9F).  
 2.2.9 Substrate profiling of NTMT1 in NTMT1 KO cell line 
Approach for the activity-based NTMT1 substrate profile assay is summarized in Fig. 2.10A. 
Lysates of NTMT1 KO cells were incubated with either SAM or Hey-SAM in the presence of 
purified wt His6-NTMT1. After click chemistry, the biotin conjugated proteins were enriched with 
streptavidin beads. Further, potential NTMT1 targets were cleaved with sodium dithionite as the 
DBA probe contains a cleavable azobenzene linker14. The purified proteins were separated on 
SDS-PAGE and visualized by Coomassie staining. The electrophoresis was only run for a short 
time (20 min) to narrow down the gel area for trypsin digestion. The pull-down samples treated 
with Hey-SAM contained significantly more proteins than the control samples which were treated 
with SAM (Fig. 2.10B). As a positive control, RCC1, one of the identified NTMT1 substrates, was 
successfully detected by WB for the samples properly labeled with Hey-SAM and click chemistry. 
Only negligible amount of RCC1 was detected in the control samples which were treated with 
click inactive cofactor SAM, validating the applicability of our protocol for NTMT1 substrate 
profiling. The lanes (Fig 2.10B) were excised, digested with trypsin and analyzed by LC-MS. Raw 
data were processed by Progenesis QI for proteomics. 
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Figure 2.10 Activity-based substrate profiling of NTMT1.  
(A) Schematic description of activity-based NTMT1 substrate profiling strategy. (B) Visualization of 
putative substrates of NTMT1 from NTMT1 KO cells by SDS-PAGE with Coomassie staining. (C) 
Detection of RCC1 from putative NTMT1 targets by WB using rabbit anti-RCC1 antibody. 
 
 2.2.10 Statistical and motif analysis of LC-MS raw data 
Mass spectrometry is a powerful and high-throughput analytical technique for proteomic study. 
MS is highly sensitivity and provides abundant information, thus it would be difficult to analyze 
the data by hands. Hence, several software has been developed to assist protein identification and 
quantification. Here, the raw data were analyzed by software Progenesis QI for proteomics and 
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our object was to identify those proteins that showed abundance differences between different 
samples (SAM treated, and Hey-SAM treated), and therefore uncover the putative targets of 
NTMT1. To minimize human errors, three replicates were performed for control sample (treated 
with SAM) and pull-down sample (treated with Hey-SAM), respectively. In Progenesis, the 
abundances of peptide ions were calculated and the analysis of variance (Anova value or p value) 
was applied to determine whether the abundance differences between groups were significant or 
not. A small Anova value indicates that the difference between groups is significant. Based on 
Anova value (≤ 0.05) and max fold change (pull down/control ≥2), 1189 protein were identified. 
The principle component analysis (PCA, Fig 2.11A) graph showed that the three replicates in each 
condition were close to each other. 
In addition, motif analysis was applied to assist the identifying of biological meaningful 
proteins. NTMT1 was previously reported to methylate proteins with an N-terminal sequence of 
Xaa (Ala/Pro/Ser)-Pro-Lys after methionine removal9. Later studies revealed that Xaa can be 
replaced with any residues except for hydrophobic Leu/Ile/Trp and negatively charged Asp/Glu 
residues12. This is in consistent with the crystal structures of NTMT1, in which the substrate 
binding pocket is negatively charged and can only provide limited space to accommodate residues 
smaller than Tyr22. Moreover, proline on the third position was predicted to be critical based on 
crystal structure analysis, however, in vitro peptide methylation assay indicated that proline could 
be substituted with asparagine, glycine, alanine, methionine or serine to some extent12. The fourth 
residue was only limited to positively charged lysine and arginine as it was demonstrated to play 
key roles in the formation of hydrogen bonding with the substrate binding channel22. Thus, the 
substrate N-terminal motif can be expanded to Xaa (Ala/Gly/Met/Pro/Ser/Thr/Tyr/Arg/Phe)-Xaa 
(Ala/Gly/Met/Asn/Pro/Ser/Thr)-Lys/Arg. Based on this expanded N-terminal sequence, 733 
57 




Figure 2.11 Statistical and motif analysis of LC-MS raw data.  
(A) Principle component analysis (PCA) (Anova value ≤ 0.05 & max fold change ≥ 2). Blue dots represent 
the three replicates for samples treated with SAM. Purple dots represent the three replicates for samples 
treated with Hey-SAM. (B) Venn diagram of putative NTMT1 targets (70 human proteins) from proteomic 
(1189 human proteins) and motif analysis (733 human proteins). (C) Subcellular distributions of putative 
NTMT1 targets. 
 
Seventy human proteins (Fig 2.11B, Table 2.3 & Appendix B) were predicted as putative 
NTMT1 targets according to the statistical and motif analysis. Among them, three of the previous 
confirmed NTMT1 substrates (highlighted in yellow in Table 2.3) including RCC1, SET and 
RL23A are included9. Subcellular location analysis showed that ~ 60% of the proteins are in 
cytoplasm and ~ 40% of the proteins are in cell nucleus.  
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Table 2.3 List of potential substrates of NTMT1 for target validation.  
The previously identified NTMT1 substrates were highlighted with yellow color; the validated targets either 
at peptide level or at protein level are highlighted with green color. Note: protein subcellular distributions 
are assigned based on UniProt database and some of the locations are predicted by similarity. 
UniProt 












P04181 OAT 13 115.58 8.47E-05 2.88 Cytoplasm  
Q5H9U9 DDX60L 5 92.45 5.94E-05 4.12 Unknown 
P62750 RPL23A 5 70.68 4.02E-05 4.77 Cytoplasm  
P18754 RCC1 4 56.32 5.01E-05 3.46 
Cytoplasm, 
nucleus  
P35232 PHB 1 43.24 0.001095 3.05 Cytoplasm  
P62263 RPS14  2 34.10 0.000113 4.20 
Cytoplasm, 
nucleus  
P04908 HIST1H2AB  1 29.50 0.00172 2.57 Nucleus 
P62805 HIST1H4A   1 26.25 0.000414 2.72 Nucleus 
Q9NTK5 OLA1  1 16.12 0.000527 3.57 
Cytoplasm, 
nucleus  
Q86U86 PBRM1  1 15.47 4.33E-06 7.29 Nucleus  
Q01105 SET 2 11.44 8.35E-05 4.14 Cytoplasm  
A1X283 SH3PXD2B  1 5.37 0.000273 2.94 Cytoplasm  
 
 2.2.11 Validation of target proteins in vitro 
NTMT1 substrates RCC1, SET and RL23A were successfully identified by this activity-based 
substrate profiling approach, suggesting that the assay worked as intended. Thus, we decided to 
select some other proteins (Table 2.3) which either have important biological functions or have 
very low or high confidence scores for in vitro validation. The open reading frames of protein 
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histone H2A type 1-B/E (H2A1B), histone H4, ornithine aminotransferase (OAT), prohibitin 
(PHB), obg-like ATPase 1 (OLA1) and 40S ribosomal protein S14 (RS14) were amplified and 
inserted into E. coli expression vectors (pET30a or pET28b) containing a C-terminal His6 tag. 
Among those proteins, only OLA1 and RS14 (Fig 2.12A, inset) were successfully purified using 
Ni-NTA resin as the other proteins were either not well expressed or existed in inclusion bodies. 
OLA1 was reported to play important roles in multiple cellular processes34-38 and therefore we 
investigated its methylation in vitro and in human cells which were described in Chapter 3. Here, 
the intact protein mass showed that the initial methionine of purified RS14 was removed (Fig. 
2.12A) and monomethylated protein (Fig. 2.12C) was detected after incubating RS14 with SAM 
and 3 µM NTMT1 for 2h at 37℃. Methylation of RS14 was enzyme-catalyzed because no 
methylated products were detected in the absence of NTMT1 (Fig. 2.12B). The major product of 





Figure 2.12 MS analysis of protein RS14 methylation with SAM and wt NTMT1.  
(A) Intact protein mass and SDS-PAGE (inset) of the purified RS14 protein (calculated MW for initial 
methionine removed RS14 [RS14 - M]: 17661.2; detected MW: 17659.49). (B) Intact protein mass of 20 
µM RS14 protein mixed with 200 µM SAM in the absence of NTMT1 (detected MW: 17659.42). (C) Intact 
protein mass of RS14 protein mixed with 200 µM SAM in the presence of 3 µM NTMT1 (calculated [RS14 
- M + CH3]: 17675.2, detected MW: 17673.22). 
 
Moreover, many identified proteins (e.g., probable ATP-dependent RNA helicase DDX60-like 
(DDX60L), protein polybromo-1 (PB1), SH3 and PX domain-containing protein 2B (SPD2B)) 
have relatively large molecular masses, thus it could be challenging to express and purify them in 
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E. coli. To simplify, we synthesized their N-terminal peptide analogs as instead. Meanwhile, the 
N-terminal peptide of protein H2A1B was also synthesized because histone H2B in Drosophila 
melanogaster was reported as a substrate for dNTMT39 and we wanted to verify whether human 
histone proteins would be methylated by human NTMT1. Peptides containing the first ten residues 
(without methionine) of PB1 (Fig. 2.13A), SPD2B (Fig. 2.14A), DDX60L (Fig 2.15A) and H2A1B 
(Fig. 2.16A) were synthesized and characterized by HPLC and LC-MS. MS-based methylation 
assay confirmed that PB1 N-terminal peptide with a GSK motif was trimethylated in the presence 
of SAM and wt NTMT1 (Fig 2.13B & 2.13C). SPD2B N-terminal peptide with a PPR motif was 
dimethylated in the presence of SAM and wt NTMT1 (Fig. 2.14B & 2.14C). To our surprise, 
DDX60L N-terminal peptide harboring the same motif as PB1 was not methylated in the presence 
of SAM and 3 µM NTMT1 (Fig. 2.15B & 2.15C). Though DDX60L and PB1 share the same GSK 
motif, their fifth residues are different. DDX60L contains a negatively charged aspartate residue 
in position 5 while PB1 contains a positively charged arginine residue. According to the crystal 
structure of NTMT1, aspartate 5 is not preferred as it locates in the entrance of a negatively charged 
channel16. In addition, H2A1B N-terminal peptide was not methylated in the presence of 200 µM 
SAM and 3 µM NTMT1 (Fig. 2.16B & 2.16C). Human H2A1B contains an SGR motif which is 
quite different from the PPK motif of H2B in Drosophila melanogaster, indicating that SGR was 
not a good substrate motif for human NTMT1.  
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Figure 2.13 MS analysis of PB1 peptide methylation with SAM and wt NTMT1.  
(A) Mass spectrum and HPLC analysis (inset) of the synthesized PB1 peptide (calculated [M + H]+: 
1114.6557; detected: 1114.6449). (B) Mass spectrum of 20 µM PB1 peptide mixed with 200 µM SAM in 
the absence of NTMT1 (calculated [M + H]+: 1114.6557; detected: 1114.6490). (C) Mass spectrum of PB1 





Figure 2.14 MS analysis of SPD2B peptide methylation with SAM and wt NTMT1.  
(A) Mass spectrum and HPLC analysis (inset) of the synthesized SPD2B peptide (calculated [M + H]+: 
1179.7326; detected: 1179.7346). (B) Mass spectrum of 20 µM SPD2B peptide mixed with 200 µM SAM 
in the absence of NTMT1 (calculated [M + H]+: 1179.7326; detected: 1179.7213). (C) Mass spectrum of 
SPD2B peptide mixed with 200 µM SAM in the presence of 3 µM NTMT1 (calculated [M + 2CH3]+: 




Figure 2.15 MS analysis of DDX60L peptide methylation with SAM and wt NTMT1.  
(A) Mass spectrum and HPLC analysis (inset) of the synthesized DDX60L peptide (calculated [M + H]+: 
1162.6122; detected: 1162.6016). (B) Mass spectrum of 20 µM DDX60L peptide mixed with 200 µM SAM 
in the absence of NTMT1 (calculated [M + H]+: 1162.6122; detected: 1162.6006). (C) Mass spectrum of 
DDX60L peptide mixed with 200 µM SAM in the presence of 3 µM NTMT1 (calculated [M + 3CH3]+: 




Figure 2.16 MS analysis of H2A1B peptide methylation with SAM and wt NTMT1.  
(A) Mass spectrum and HPLC analysis (inset) of the synthesized H2A1B peptide (calculated [M + H]+: 
944.5390; detected: 944.5300). (B) Mass spectrum of 20 µM H2A1B peptide mixed with 200 µM SAM in 
the absence of NTMT1 (calculated [M + H]+: 944.5390; detected: 944.5315). (C) Mass spectrum of H2A1B 
peptide mixed with 200 µM SAM in the presence of 3 µM NTMT1 (calculated [M + 3CH3]+: 986.5859, 
detected: 944.5324). 
 
Taken together, validation of NTMT1 putative targets revealed protein RS14 as NTMT1 
targets in vitro. In addition, the N-terminal peptides of PB1 and SPD2B was tri- and dimethylated 
with NTMT1 respectively, suggesting that their corresponding proteins are likely to be methylated 
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by NTMT1. Moreover, the importance of the fifth residue adjacent to Xaa-Xaa-Lys/Arg motif may 
be previously underestimated as DDX60L peptide containing a GSKD motif cannot be methylated 
while PB1 peptide with a GSKR motif can be trimethylated.    
To summarize, target validation demonstrated that protein RS14 and the N-terminal peptide 
analogs of PB1 and SPD2B were NTMT1 substrates in vitro. In addition, lots of the candidate 
substrates have important biological functions. For example, the bromodomain containing protein 
PB1 functions as a “reader” for histone lysine acetylation and it plays important roles in 
maintaining the chromosomal stability40-41. Thus, it would be meaningful to investigate its 
methylation at protein level in future. Moreover, OLA1 was reported to play important roles in 
multiple cellular processes including regulation of centrosome, heat shock response and cell 
growth34-38, and therefore we decided to investigate its methylation in vitro and in vivo which were 
described in Chapter 3.  
 2.3 Materials and methods 
 2.3.1 General information 
Unless otherwise specified, HPLC was performed with a Breeze 2 system consisting of a 1525 
pump and 2998 photodiode array detector (Waters). High-resolution mass spectroscopy was 
acquired with an Acquity H-class or M-class UPLC coupled with XEVO G2-XS QTof (Waters). 
To determine the intact protein mass, proteins were separated by either a BEH C4 column (1.7 
m, 300 Å, 2.1 mm  50 mm, for H class UPLC, Waters) or an M-class BEH C4 (1.7 m, 300 Å, 
300 m  150 mm, Waters) with an M-class BEH C4 trap column (5 m, 300 Å, 300 m  50 
mm, Waters). For small molecules, synthesized peptides, peptides mapping, protein identification 
and quantification, either a BEH C18 (1.7 m, 130 Å, 2.1 mm  50 mm, for H class UPLC, Waters) 
or an M-class HSS T3 column (1.8 m, 100 Å, 300 m   100 mm, Waters) with an M-class 
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symmetry C18 trap column (5 m, 100Å, 300 m   50 mm, Waters). Mobile phase A and B 
consisted of 0.1% formic acid in water and acetonitrile, respectively. HPLC samples were 
centrifuged to remove particles before injection. MS samples were filtered using either 0.2 μm 
PTFE syringe filters (Fisher Scientific) or ultrafree PTFE membranes (Millipore). NMR spectrums 
were obtained on a 400 MHz (Varian) or 600 MHz (Bruker) spectrometer.  
 2.3.2 Plasmids construction 
Human NTMT1 gene was synthesized by Genscript and amplified by polymerase chain 
reaction (PCR) to introduce restriction sites NdeI and HindIII.  Human RCC1 gene was amplified 
from pST50Tr-hRCC1 (generous gift from Dr. Tan’s lab)42 to introduce NdeI and XhoI restriction 
sites. The open reading frames of protein RS14, PHB, OAT, H2A1B and H4 were amplified from 
the complementary DNA (cDNA) originated from HEK293FT cell line. The amplified PCR 
products and vectors were digested with the corresponding restriction endonucleases. NTMT1 
gene was inserted into pET28-MHL (Addgene) to generate pET28-MHL-NTMT1 containing an 
N-terminal His6 tag. Genes of RCC1, PHB, OAT, H2A1B and H4 were inserted into vector 
pET30a containing a C-terminal His6 tag. RS14 gene was inserted into pET28b vector to generate 
pET28b-RS16 containing a C-terminal His6 tag.  
To generate NTMT1 KO cell line using CRISPR-Cas9 system, guide sequences were designed 
according to an online CRISPR Design Tool (http://tools.genome-engineering.org) established by 
Dr. Zhang group33. The synthesized oligos were annealed to give sticky BbsI ends and inserted 
into the BbsI digested vector PX459 (generous gift from Dr. Xiong lab) which contains single 
guide RNA scaffold, cas9 coding sequence and puromycin selection marker. 
All the insertions were verified by DNA sequencing before use. The sequences of all used 
primers are listed in Table 2.4. 
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Table 2.4 Primer sequences for plasmids construction.  
The restriction sites are bolded and underlined. 












HindIII_Rv TTTTTTAAGCTTCAGACGGCGACCACGGCGACC C 
pET30a-PHB NdeI_Fw AACCCACATATGGCTGCCAAAGTGTTTGAGTC 
XhoI_Rv AAAATTCTCGAGCTGGGGCAGCTGGAGGAGCAC 





















 2.3.3 Cell culture conditions 
Human embryonic kidney 293FT cells (generous gift from Dr. Yulan Xiong) and the NTMT1 
gene KO cells were cultured in Dulbecco’s Modification of Eagle’s Medium (DMEM, with 4.5 
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g/L glucose, L-glutamine & sodium pyruvate, Corning cellgro) supplemented with 10% fetal 
bovine serum (heat inactivated FBS, Gibco) and 1% penicillin-streptomycin (P/S, Gibco) in a 
humidified atmosphere containing 5% CO2 at 37 C.  
 2.3.4 Expression and purification of recombinant proteins 
Plasmids pET28-MHL-NTMT1, pET28b-RS14, pET30a-PHB, pET30a-OAT, pET30a-
H2A1B and pET30a-H4 were transformed into E. coli BL21(DE3) competent cells (Lucigen). 
Plasmid pET30a-RCC1 was transformed into E. coli C41 (DE3) competent cells (Lucigen). 
Bacterial were grown in 4L of Luria-Bertani (LB) medium in the presence of 50 μg/ml kanamycin. 
Isopropyl β-D-1-thiogalactopyranoside (IPTG, 0.4 mM as the final concentration) was added into 
the culture to induce the expression of recombinant proteins when OD600 nm reached to 0.6 - 0.8. 
Bacterial were then cultured for additional 18 h at 18 ℃ and harvested by centrifugation at 5,000 
× g for 20 min at 4 ℃. Cell pellets were collected and frozen at -80 ℃ for further use. 
The ingredients of buffers used in this study are summarized in Table 2.5. Protein purification 
was performed at 4 ℃. Briefly, bacterial pellets were suspended and lysed in buffer A by 
sonication for 15 min (5-second on and 3-second off) at 40% amplitude. After centrifugation at 
18,000 × g for 45 min at 4 ℃, the cell debris was removed, and the supernatant were incubated 
with Ni-NTA resin (Qiagen) which had been previously equilibrated with buffer A for 30 min. 
After washing with 30 column volumes (CV) of buffer B, recombinant proteins containing the 
His6 tag were eluted with 5 CV of buffer C. The eluted fractions containing the target protein were 
combined and exchanged to buffer D using either a HiPrepTM 26/10 desalting column (GE 
Healthcare) or Amicon Ultra-15 Centrifugal Rilter Unites (30 kDa or 10 kDa, Millipore). Proteins 
were further exchanged to 10 mM ammonium bicarbonate (ABC) for determining their intact 
protein masses. Proteins were further concentrated to 10-50 mg/ml, flash frozen with liquid N2 and 
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stored in aliquots at -80 ℃ for further use. Protein purity was examined by 12% tris-tricine or tris-
glycine SDS-PAGE and their concentrations were determined by bicinchoninic acid assays (BCA, 
ThermoFisher) using a BSA calibration curve. 
 
Table 2.5 Ingredients of buffers and click chemistry cocktail. 
Buffer Composition 
A 25 mM HEPES (pH 7.4), 300 mM NaCl and 5 mM Imidazole 
B 25 mM HEPES (pH 7.4), 300 mM NaCl and 30 mM Imidazole 
C 25 mM HEPES (pH 7.4), 300 mM NaCl and 250 mM Imidazole 
D 25 mM HEPES (pH 7.4), 150 mM NaCl and 50 mM KCl 
E 25 mM Tris (pH 7.5) and 50 mM KCl   
F 25 mM HEPES (pH 7.4), 150 mM NaCl and 1% SDS 
G 25 mM HEPES (pH 7.4) and 300 mM NaCl  
H 1% SDS in 1 × PBS (pH 7.4) 
I 1 × PBS (pH 7.4) 
J 4 M urea in 1× PBS (pH 7.4)  





one volume of 5 mM DBA and ten volumes of premixed solution 
consisting of 1 mM TBTA, 10 mM CuSO4, and 10 mM TCEP (pH was 
adjusted to 7.0 using 1 M NaOH) 
 
 2.3.5 Peptide synthesis 
RCC1 peptide [SPKRIAKRRS(CONH2)], PB1 peptide [GSKRRRATSP(CONH2)], SPD2B 
peptide [PPRRSIVEVK(CONH2)], DDX60L peptide [GSKDHAVFFR(CONH2)], and histone 
H2A1B peptide [SGRGKQGGKA(CONH2)] were synthesized on Rink amide resins (Peptide 
International) using standard Fmoc chemistry43. The synthesized peptides were characterized by 
71 
HPLC and mass spectrometry. RCC1 peptide and SPD2B peptide were further purified through 
semi-preparative HPLC. The conditions of analytical and semi-preparative HPLC are summarized 
in table 2.6. 
 
Table 2.6 HPLC conditions for peptide purification and characterization.  
 Semi-preparative HPLC Analytical HPLC 
Column Luna C18(2), 5 m, 100 
Å, 10 mm  250 mm 
(Phenomenex) 
XBridge BEH Shield RP 
18, 5 m, 130 Å, 4.6 mm 
 250 mm (Waters) 
Flow Rate 3.0 mL/min 1.0 mL/min 











0-5 min: 5%; 5-30 min: 
5%-30% 
(23.7 min) 








0-40 min: 10%-40% 
(18.3 min) 








N/A 0-30 min: 1%-15%; 
(4.3 min) 
 
 2.3.6 MS-based methylation and alkylation assay for RCC1 peptide and protein 
Methylation and alkylation of RCC1 at peptide and protein levels by wt NTMT1 and cofactors 
were investigated using mass spectrometry. Specifically, 20 μM RCC1 peptide dissolved in 10 
mM ABC or RCC1 protein dissolved in buffer D, 200 μM SAM or Hey-SAM, and 3 μM wt 
NTMT1 were mixed and incubated at 37 C for 2 h. Negative controls were performed in the 
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absence of wt NTMT1. The peptide reaction mixtures were quenched with equal volume of water 
containing 0.1% formic acid and then analyzed by LC-MS. The protein reaction mixtures were not 
quenched and directly analyzed by LC-MS, which was performed on a M-class BEH C4 column 
eluted at a flow rate of 0.4 mL/min. The gradient for intact protein mass analysis was: 0-1 min, 
5% B; 1-3.5 min, 5%-100% B; and 3.5-4.7 min, 100% B. Elution from 2−4.7 min was injected 
into the mass spectrometer, which was operated in a MS mode with a positive polarity. Raw data 
of intact protein mass were processed by BiopharmaLynx (Waters).  
 2.3.7 HPLC-based steady state kinetic study  
The steady state kinetics were performed by measuring the SAH release using HPLC.  The 
concentrations of SAH formed were quantified by adenosine which served as an external standard. 
Experiments were performed by varying concentrations of one substrate in the presence of the 
other one at saturation. Specifically, concentrations of SAM and Hey-SAM varied from 0.1 to 8 
μM and from 0.2 to 16 μM, respectively, in the presence of 40 μM RCC1 peptide. Concentration 
of RCC1 peptide varied from 0.5 to 16 μM in the presence of 20 μM SAM or Hey-SAM. 
Experiments were carried out in the following way. In a final volume of 400 μL, 0.3 μM wt 
NTMT1 was added to the mixtures of cofactor and RCC1 peptide in buffer E at 37 C. Aliquots of 
40 μL were withdrawn at selected time intervals (1 to 90 min) and the reactions were quenched 
with 40 μL of 0.4% TFA solution containing 4 μM adenosine. The reaction mixtures were 
centrifuged at 18,000 × g for 2 min and 40 μL of the supernatant were injected into an XBridge 
Shield RP 18 column (3.5 μm, 130 Å, 4.6 mm × 150 mm, Waters) using an autosampler (Agilent). 
The mobile phase contained an isocratic gradient of 1% methanol in water supplemented with 
0.01% TFA and the flow rate was 1 ml/min. Measurements were performed in triplicate. 
Concentrations of SAH were determined by area ratios of the peaks corresponding to SAH and 
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) using SigmaPlot.  
 2.3.8 Isothermal titration calorimetry  
ITC measurements were carried out with MicroCal iTC200 (GE Healthcare) at 25 C. Purified 
wt NTMT1 was diluted to a final concentration of 50 μM using buffer D. Cofactors or RCC1 
peptide were dissolved and diluted to 300-500 μM using the same buffer. For titration, the first 
syringe injection volume was 0.5 μl and the volume for the following 18 injections was 2 μl. The 
interval between each injection was 180 s and the reference power was 7 μcal/s. Measurements 
were performed in duplicate. 
 2.3.9 Verification of RCC1 modification site by in-gel trypsin digestion and peptide 
mapping 
To identify the modification site of RCC1 protein by Hey-SAM and wt NTMT1, the alkylation 
reaction mixture was separated by SDS-PAGE. In-gel trypsin digestion for LC-MS analysis was 
performed following the standard protocol44. Briefly, the target gel band was excised, cut into 1.0 
mm3 pieces, reduced with 100 mM dithiothreitol (DTT), and then alkylated with 55 mM 
iodoacetamide. After dehydration with acetonitrile, protein digestion was implemented with 
sequencing-grade trypsin (Promega) at 20 ng/µL in 10 mM ABC containing 10% (vol/vol) 
acetonitrile at 37 C for 18 h. After extraction with 100 μl of 5% fomic acid, 100 μl of 100% 
acetonitrile/10% fomic acid (1:1, vol/vol), and 100 μl of pure acetonitrile, respectively, the 
digestion products were further concentrated by SpeedVac. 
For LC−MS analysis, peptides were re-dissolved in water containing 5% formic acid and 
separated on an BEH C18 column. The flow rate for mobile phase was 0.2 mL/min and the gradient 
of mobile phase B increased from 0 to 50% in 50 min. The mass spectrometer was operated in an 
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MSE mode with a ramp collision energy ranging from 20 to 45 V. Raw data were analyzed by 
BiopharmaLynx (Waters). The parameters for peptide mapping included peptide mass tolerance 
of 10 ppm, MSE mass tolerance of 30 ppm, no missed cleavages allowed, fixed modification of 
cysteine carbamidomethylation and variable modification of N-terminal chain by Hey. 
 2.3.10 Detection of biotin labeled RCC1 protein 
In a final volume of 200 μl, 20 μM purified RCC1 was incubated with 50 μM Hey-SAM and 
3 μM wt NTMT1 in buffer D at 4 C for overnight. Negative controls were carried out either using 
SAM to substitute Hey-SAM or in the absence of wt NTMT1. Cold methanol (1 ml) were added 
to the mixtures to precipitate proteins. After centrifuging at 14,100 × g for 2 min and removing the 
supernatant, protein pellets were washed with 1 mL cold methanol for three times, air-dried for 15 
min, and re-dissolved in 200 μL buffer F. A total volume of 22 μL click chemistry cocktail (Table 
2.5) were added into each sample and the click reaction was performed in the dark for 2 h at room 
temperature15. Proteins were then precipitated with 1 mL cold methanol and kept overnight at −80 
C. After washing with 1 mL cold methanol, the protein pellets were re-dissolved in 100 μL buffer 
F. Presence of RCC1 and biotin were verified by Western blot (WB) as described below in Section 
2.4.12 using rabbit anti-RCC1 antibody (Abcam) and streptavidin-HRP (SA-HRP, Abcam), 
respectively.  
The biotin labeled RCC1 were separated from non-labeled RCC1 using gel shift assay with 
streptavidin. Briefly, 10 μL of the above re-dissolved protein samples after click chemistry were 
mixed with 10 μL of 2  Laemmli buffer and denatured at 100 C for 5 min. After cooling down 
to room temperature, the samples were incubated with 15 μL of 1mg/ml streptavidin solution 
(NEB) at room temperature for 30 min45 and separated by SDS-PAGE. Bands corresponding to 
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the RCC1-streptavidin complexes were excised and analyzed following the procedures for in-gel 
trypsin digestion and peptide mapping described in Section 2.4.9.  
 2.3.11 Pull-down of overexpressed RCC1 from E. coli lysates via activity-based 
substrate profiling strategy 
E. coli C41(DE3) cells transformed with pET30a-RCC1 were cultured and harvested as 
described above in Section 2.4.4. Bacterial pellets were re-suspended in buffer G, sonicated for 15 
min (5-second on and 3-second off) at 40% amplitude and centrifuged at 18,000 × g for 45 min. 
The supernatant (1 ml) were withdrawn and incubated with 50 μM Hey-SAM and 3 μM wt 
NTMT1 overnight at 4 C. Negative controls were carried out either using SAM to substitute Hey-
SAM or in the absence of wt NTMT1. Proteins were precipitated out by adding 4 mL cold 
methanol, air-dried for 15 min, and re-dissolved in 4 mL buffer F. A total volume of 440 μL click 
chemistry cocktail (Table 2.5) were added to each sample and click chemistry was performed in 
dark for 2 h at room temperature15. Proteins were precipitated out by adding 16 mL cold methanol, 
re-dissolved in 1 mL buffer H and incubated with 60 μL streptavidin beads (prewashed with buffer 
I, GE Healthcare) for 2 h at room temperature with gentle shaking. Samples were centrifuged at 
4,000 × g for 2 min and the supernatant containing unbound proteins were pipetted out. The 
streptavidin beads were then washed sequentially with buffer I, buffer J, and 100 mM ABC, each 
for three times. Finally, the biotin labelled proteins were cleaved and eluted from the beads using 
60 L of 25 mM sodium dithionite in 20 mM ABC. The eluted proteins were mixed with 2 × 
Laemmli buffer and analyzed by SDS-PAGE. Presence of RCC1 was detected and quantified by 
western blot as described below in Section 2.4.12. Standard curve of signal volumes versus protein 
amounts were generated using a dilution series of purified RCC1 from E. coli with known 
concentrations.  
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 2.3.12 Western blot 
Equal volumes of cell lysates or protein samples were separated in a 12% tris-glycine SDS-
PAGE and then transferred to a supported nitrocellulose membrane (Bio-Rad). The membranes 
were incubated with rabbit anti-RCC1 antibody (1:1000, Abcam), rabbit anti-NTMT1 antibody 
(1:1000, Abcam), or streptavidin-HRP (1:3000, Abcam) overnight at 4 C. After washing with 
TBS-T (0.1% Tween 20 in 1 × TBS) buffer, membranes for RCC1 or NTMT1 detection were 
incubated with goat anti-rabbit antibody (1:5000, Abcam) by gentle shaking for 1 h at room 
temperature. Upon similar washing, bands were detected using SuperSignal West Pico PLUS 
chemiluminescent substrate (Thermo Fisher Scientific) following manufacturer’s protocol. The 
bands were visualized using Amersham Imager 600 (GE Healthcare). 
 2.3.13 NTMT1 knockout using CRISPR-Cas9 system 
Procedures for knockout of NTMT1 gene in HEK293FT cell line were similar to the published 
nature protocal33. Briefly, 1 μg of plasmids PX459-NTMT1sgRNA1 and 1 μg of PX459-
NTMT1sgRNA2 were mixed and transfected to HEK293FT seeded in a 6-well plate using 
transfection reagent LipoD293 (SignaGen Laboratories) and Opti-MEM® I Reduced Serum 
Medium (ThermoFisher) when cell confluency reached to 50%-70%. After 36h, transfected cells 
were treated with 3 μg/ml puromycin for 1 week. Cells were then dissociated with TrypLE™ 
Express Enzyme (ThermoFisher), counted and serially diluted in DMEM supplemented with 20% 
FBS to a final cell density of 50-100 cells per 15 ml medium to reduce the possibility of having 
multiple cells in one well. The diluted cells were plated to two 96-well plates and cultured for 2 
weeks. After passaging to 24-well pate, cells were screened by western blot using anti-NTMT1 
antibody (Abcam). For those cells without the expression of NTMT1, their genome DNAs were 
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extracted with Tissue DNA Kit (Omega), and the exon1 of NTMT1 were amplified and sequenced. 
After confirmed by DNA sequencing, the NTMT1 KO cell lines were frozen in liquid N2. 
 2.3.14 Activity-based NTMT1 substrate pull-down and proteomic identification of 
NTMT1 targets in NTMT1 KO cell line 
The culture condition for NTMT1 KO cells was described in Section 2.4.3. At 70%−90% 
confluence stage, cells (4 of 175 cm2 flasks) were harvested and lysed in 9 mL cold buffer K by 
sonication for 8 min (5-second on and 3-second off) at 40% amplitude. Cell lysates were 
centrifuged at 15,000 × g for 15 min at 4 C to remove cell debris. The supernatant was incubated 
with either 50 μM Hey-SAM or SAM (negative control) in the presence of 3 μM wt NTMT1 for 
4 h at 37 C. Four-time volumes of cold methanol was added into each sample and kept at −80 C 
overnight to precipitate proteins. The samples were centrifuged at 7,197 × g for 30 min and the 
supernatant was removed. The protein pellets were air-dried for 15 min and re-dissolved in 4.0 mL 
buffer F. Click chemistry and subsequent treatment were performed in the same way as described 
above in Section 2.4.11. As a positive control, the presence of RCC1 was detected by western blot 
as described above in Section 2.4.12. 
The lanes of Hey-SAM and SAM (negative control) treated were excised and digested with 
trypsin following the procedure described in section 2.4.9. For LC-MS analysis, protein digestion 
products were re-dissolved in water containing 1% formic acid, filtered with Ultrafree PTFE 
membrane (Millipore) and injected to a M class UPLC-XEVO G2-XS QTof (Waters) equipment. 
Peptides were firstly cleaned by a trapping column (ACQUITY UPLC M-Class Symmetry C18 
Trap Column, 100 Å, 5 µm, 300 µm × 50 mm, Waters) and separated on an analytical column 
(ACQUITY UPLC M-Class HSS T3 Column, 1.8 µm, 300 µm × 100 mm, Waters) with a flow 
rate of 8 ul/min. Mobile phase A and B consisted of 0.1% formic acid in water and acetonitrile, 
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respectively. The gradient for separation is 1 % to 40 % of mobile phase B for 45 min. The mass 
spectrometer was operated in positive polarity, sensitivity mode, and an MSE mode with a ramp 
collision energy ranging from 20 to 45 V. Raw data were analyzed by Progenesis QI for Proteomics 
(Waters). The statistical and motif analysis were described in Section 2.2.11. 
 2.3.15 Targets validation via MS-based methylation assay 
MS-based methylation assays of RS14 protein, PB1 peptide, SPD2B peptide, DDX60L peptide 
and histone H2A1B peptide were performed similarly to the previous described procedure in 
Section 2.2.6 except that the MS data were acquired on a M class UPLC coupled with XEVO G2-
XS QTof (Waters). Raw data of peptides were processed by MassLynx (Waters) and raw data of 
intact protein mass were analyzed by BiopharmaLynx (Waters). 
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Chapter 3 - Investigation of hOLA1 methylation in vitro and in 
human cells 
 3.1 Introduction 
 3.1.1 Obg-like ATPase 1 (OLA1) 
Nucleotide binding proteins (e.g., kinases, ATPases, GTPases) are one of the most important 
families of proteins which play vital roles in multiple cellular processes including cation transport, 
protein translation, signal transduction, mRNA transcription, microRNA biogenesis, cell motility, 
DNA replication, mitosis and cytoskeleton organization1-8. Obg-like ATPase 1 (OLA1) belongs to 
the family of P-loop GTPases, however, preferentially binds and hydrolyzes ATP over GTP in 
vitro9. Koller-Eichhorn et al. solved the crystal structure of hOLA1 (PDB: 2OHF) and explained 
that the hydrogen bonding between the carbonyl group of Leu 231 and the exocyclic amino group 
in ATP was responsible for its preferred binding with ATP9. 
OLA1 was also named as DNA damage-regulated overexpressed in cancer 45 (DOC45) 
because it was strongly downregulated by DNA damage-inducing chemicals (e.g., doxorubicin, 
etoposide) and UV radiation10. Sun et al. reported that OLA1 was overexpression in several 
different human cancers (e.g., colorectal, rectum, stomach, lung, ovary, uterus) and oncogenic 
mutant of H-Ras or TC21 significantly increased the expression of OLA110. Recent studies 
indicated that OLA1 have multiple roles in several cellular processes including centrosome 
amplification, antioxidant response, heat shock response and cell growth10-15. 
 3.1.2 OLA1 regulates centrosome amplification 
OLA1 was reported to directly interact with breast cancer type 1 susceptibility protein 
(BRCA1), BRCA1-associated RING domain protein (BARD1) and γ-tubulin (a centrosome 
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marker)11, 16. Knockdown of OLA1 resulted in abnormal amplification of centrosome in breast 
cancer cell lines (e.g., Hs578T) which was rescued by overexpression of wt OLA1 but not the 
OLA1 E168Q mutant11. OLA1 E168Q mutant failed to bind to BRCA1, and therefore, OLA1 may 
regulate centrosome amplification by binding with BRCA1 protein11. Moreover, Yoshino et al. 
reported that overexpression of wt OLA1 in breast cancer cell line Hs578T caused abnormal 
centrosome amplification while the overexpression of OLA1 E168Q mutant did not result in extra 
amplification of centrosome12. These results suggest that either downregulation or upregulation of 
OLA1/BRCA1 complex would affect the centrosome amplification and keeping a regular 
expression level of OLA1 is necessary for maintaining the normal numbers of centrosome.  
 3.1.3 OLA1 functions as an antioxidant suppressor for oxidative stress 
Oxidative stress refers to the oxygen toxicity by oxidants (e.g., hydrogen peroxide)17. Zhang 
et al. reported that HeLa cells with OLA1 knockdown by siRNAs exhibited enhanced resistance 
to oxidative agents (e.g., hydrogen peroxide, tert-butyl hydroperoxide), while the overexpression 
of OLA1 in HeLa cells increased cell cytotoxicity induced by tert-butyl hydroperoxide13. 
Moreover, lower amount of reactive oxygen species (ROS) were observed in OLA1-knockdown 
HeLa cells compared to normal HeLa cells after the treatment of tert-butyl hydroperoxide13. In 
addition, the concentration of glutathione (GSH), a vital chemical in protecting cells from 
oxidative toxicity, remained a high level in OLA1-knockdown HeLa cells but dramatically 
decreased in normal HeLa cells after treatment with tert-butyl hydroperoxide13. All these results 
demonstrate that OLA1 regulates cellular oxidative stress by acting as an antioxidant suppressor13.   
 3.1.4 OLA1 regulates the stability of heat shock protein 70 (HSP70)  
Heat shock protein 70 (HSP70) belongs to the family of heat shock proteins and functions as 
a molecular chaperone to assist the folding of newly synthesized proteins, unfolding and refolding 
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of damaged or aggregated proteins18. Mao et al. reported that knockdown or knockout of OLA1 
gene in cultured cells (e.g., MDA-MB-231, mouse embryonic fibroblast cells (MEFs)) enhanced 
the cells’ sensitivity towards heat shock treatment (42 ℃ and 45 ℃) compared to normal cells14. 
Moreover, overexpression of OLA1 in HEK293T cells increased cell survival after heat shock 
treatment14. These results indicate that OLA1 act as a regulator for heat shock response. Further, 
the expression level of HSP70 was dramatically decreased in either OLA1 KO MEFs or OLA1 
knockdown human cell lines (e.g., MDA-MB-231, HEK293T), demonstrating that OLA1 
regulated the expression of HSP7014. Overexpression of OLA1 in either MDA-MB-231 or 
HEK293T cells caused an increased expression level of HSP7014. Further study indicated that 
downregulation of OLA1 did not have a significant influence on the transcription of HSP7014. To 
investigate the regulation mechanism, co-IP of OLA1 and C-terminal domain of HSP70 was 
performed and OLA1 was found to bind with HSP7014. Further study revealed that the interaction 
of OLA1 with HSP70 blocked the binding site for CHIP (carboxy terminus of HSP70-binding 
protein), impeded the CHIP induced ubiquitination of HSP70 and therefore stabilized HSP7014, 19. 
These results suggest that OLA1 regulates the stability of HSP70 via a post translational 
modification mechanism14.  
 3.1.5 OLA1 regulates cell growth 
Overexpression of OLA1 is found in many types of cancers, thus OLA1 has been proposed to 
influence cell growth10. Sun et al. reported that OLA1 knockdown in two cultured human colon 
cancer cell lines (RKO and HT29) had a negative effect on cellular proliferation10. In contrast to 
this in vitro study, xenograft experiments performed by Chen et al. showed that OLA1-knockdown 
MDA-MB231 cells grew into larger and heavier tumors compared to normal cells when they were 
inoculated into nude mice15. Terminal deoxynucleotidyl transferase dUTP nick end labeling 
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(TUNEL) assay indicated that OLA1 knockdown cells had a lower apoptotic rate. Moreover, the 
downregulation of CCAAT/enhancer-binding protein-homologous protein (CHOP) which plays 
critical role in regulating apoptosis20-21, was observed in OLA1-knockdown tumors15. All these 
results suggest that the accelerative tumor growth for OLA1 knockdown breast cancer cells results 
from a net decreased cell death with a normal cell growth but a low apoptosis15.  
 3.1.6 Phenotypes of OLA1 knockout mice 
To study the physiological functions of OLA1, Ding et al. generated OLA1 knockout mice22. 
Though the heterozygous mice (Ola1+/-) looked similar to the normal mice, 80% the homozygous 
mice (Ola-/-) died within 24 h of birth22. The survived homozygous mice had smaller body size, 
decreased body weight and delayed cell proliferation compared to control mice22. The upregulation 
of protein cyclin-dependent kinase inhibitor 1 (p21) in OLA1 knockout MEFs was observed and 
p21 knockout in Ola1-/- mice (p21-/-/Ola1-/-) partially rescued the growth defects22. Protein p21 is 
known as an inhibitor for cyclin-dependent kinases mediated protein phosphorylation and may 
arrest the cell cycle23-24. These results indicate that OLA1 may be involved in regulating p21 
expression. The accumulation of p21 in Ola1-/- mice inhibited the cell proliferation, which partially 
explained why the Ola1-/- mice exhibited the delayed progression of development22.    
 3.1.7 Purpose of this study 
The activity-based substrate profiling of NTMT1 (Chapter 2) revealed OLA1 as one of the 
putative targets (Table 2.3). In addition, OLA1 contains an N-terminal Met-Pro-Pro-Lys-Lys 
motif, which was predicted to be the best one for NTMT1 substrates25. Previous studies 
demonstrated that NTMT1 was mainly localized in cell nucleus26-27. Many of the identified 
substrates (e.g., DDB2, RCC1) have the same subcellular localization as NTMT1 in the nucleus28-
29. Human OLA1 was reported to localize in both cytoplasm and nucleus but with a major 
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distribution in cytoplasm10. Moreover, treatment with leptomycin B, a nuclear export inhibitor, 
significantly enhanced the nucleus distribution of endogenous OLA1 in MCF-7 cells10. These 
results indicate that OLA1 exhibited a unique nucleocytoplasmic subcellular localization10. Taken 
together, we hypothesized that OLA1 would be a candidate substrate for NTMT1 and therefore 
we investigated its methylation in vitro and in vivo.  
 3.2 Results and discussion 
 3.2.1 Methylation of OLA1 peptide by NTMT1 
To investigate whether OLA1 would be methylated by wt NTMT1, we firstly synthesized its 
peptide equivalent (OLA1 peptide, Fig. 3.1A) which contains the first 10 N-terminal residues 
without the initial methionine and used it as the substrate for methylation reaction. The reaction 
products, methylated peptide and SAH, were analyzed by MS and HPLC, respectively. MS 
analysis showed that OLA1 peptide methylation was enzyme-catalyzed (Fig. 3.1B & 3.1C) and 
OLA1 peptide was fully converted into dimethylated product (Fig. 3.1C) after incubating with 
SAM and 1 µM NTMT1 for 30 min at 37 ℃. SAH release was monitored by HPLC (Fig. 3.1D) 
and quantified using adenosine as an external reference. The initial rate for the reaction between 
100 µM SAM and 40 µM OLA1 peptide with 1 µM NTMT1 was 2.17 µM/min (Fig. 1E) which is 
higher than the value for RCC1 peptide (0.58 min) at the same condition. This result is in 
accordance with the previous reported ITC results which indicated that Pro-Pro-Lys was a better 





Figure 3.1 MS and HPLC analysis of OLA1 peptide methylation.  
All reactions were carried out at 37 ℃. (A) Mass spectrum and HPLC purity (inset) of the synthesized 10-
residue OLA1 peptide (calculated [M + H]+: 995.6002, detected: 995.5836). (B) Mass spectrum of the 
reaction between 20 μM OLA1 peptide and 200 μM SAM in the absence of NTMT1 (calculated [M + H]+: 
995.6002, detected: 995.5992). (C) Mass spectrum of the reaction between 20 μM OLA1 peptide and 200 
μM of SAM with 1 μM NTMT1 (calculated [M + 2CH3]+: 1023.6315, detected: 1023.6260). (D) HPLC 
monitoring of SAH release for the reaction between 40 μM of OLA1 peptide and 100 μM of SAM with 1 
μM NTMT1 at different time intervals. (E) Initial rate of SAH release for the reaction described in (D).  
 
 3.2.2 Methylation of OLA1 protein in vitro by NTMT1 
To examine whether NTMT1 could catalyze OLA1 methylation at the protein level, 
recombinant wt OLA1 (Fig. 3.2 A) with a His6 tag on its C-terminus was expressed and purified 
from E. coli. Removal of the initial methionine residue is a common modification in E. coli30-31. 
However, the reported catalytic activity of E. coli methionine aminopeptidase 1 (MAP1) towards 
substrate peptides containing a proline at the third position was very low32. As described in chapter 
2, the initial methionine of RCC1 can be partially or completely removed when expressed in E. 
coli, and thus we decided to check the intact protein mass of OLA1 before performing the 
methylation assay. Here, the MS results indicated that the initial methionine of wt hOLA1 
expressed in E. coli was completely cleaved (Fig. 3.2B). Protein in-gel chymotrypsin digestion 
and subsequent LC-MS analysis confirmed the initial methionine removal of OLA1 (Fig. 3.2C, 
retention time: 20 min). Purified OLA1 was directly used as a substrate for methylation assay. 
Dimethylated OLA1 protein was only detected in the sample containing both SAM and NTMT1, 
indicating that OLA1 methylation is enzyme-catalyzed (Fig. 3.2D & 3.2E). Note that the 
dimethylation of proline would introduce a positive charge for OLA1, which would make the 
deconvoluted intact mass processed by BiopharmaLynx software (Waters) one Dalton lower than 
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the theoretical mass. In-gel chymotrypsin digestion of methylated OLA1 and subsequent analysis 
by LC-MS verified this protein N-terminal methylation (Fig. 3.2F). To further confirm that the 
mass shift was caused by NTMT1 and SAM, the SAH release was monitored and quantified by 
HPLC (Fig. 3.2D & 3.2E inset). In consistent with MS results, 31.4 μM of SAH were formed for 





Figure 3.2 MS and HPLC analysis of OLA1 protein methylation.  
All reactions were carried out at 37 ℃. (A) Plasmid construction (left panel: amplification of OLA1 gene 
from human cDNA) and protein purification (wt OLA1: 45 kDa). (B) Intact protein mass of wt hOLA1 
(calculated MW for deletion of initial methionine [wt hOLA1 - M]: 45677.5 Da, detected MW: 45676.75 
Da). (C) MSE spectrum of mapping the wt OLA1 N-terminal peptide (calculated precursor ion: 1874.1011, 
detected: 1874.0760). (D) Intact protein mass of wt hOLA1 after incubating with SAM (detected MW: 
45676.87 Da) and HPLC monitoring of SAH release (inset). (E) Intact protein mass of wt hOLA1 after 
incubation with SAM and NTMT1 (calculated [wt hOLA1 – M + 2CH3]: 45706.56Da, detected MW: 
45705.05 Da) and HPLC monitoring of SAH release (inset). (F) MSE spectrum of mapping the dimethylated 
wt OLA1 N-terminal peptide (calculated precursor ion: 1902.1324, detected: 1902.1045). 
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 3.2.3 The importance of Pro-Pro-Lys motif for OLA1 N-terminal methylation  
Considering the importance of lysine residue in the Xaa-Pro-Lys motif and its glutamine 
mutant dramatically affected the methylation of RCC128 and DDB229, we decided to examine its 
importance for OLA1. The peptide containing the lysine to glutamine mutation (OLA1 K4Q 
peptide) was synthesized and characterized by HPLC (Fig. 2.3A inset) and MS (Fig. 2.3A). MS 
analysis of methylation assay showed that NTMT1 was not able to catalyze the methylation of 
OLA1 K4Q peptide (Fig. 2.3B & 2.3C). Compared to PPK peptide, the SAH release for the 
mixture of 100 µM SAM, 40 µM PPQ peptide and 1 µM NTMT1 was negligible (Fig. 2.3D) and 
the initial reaction rate was only 0.017 µM/min (Fig. 2.3E). These results indicate that lysine 
residue in the Pro-Pro-Lys motif is vital for OLA1 N-terminal methylation. 
Next, we examined whether Lys 4 is important for OLA1 methylation at the protein level. The 
K4Q mutant (Fig. 2.3F, inset) was generated, expressed and purified from E. coli. Unlike wt 
OLA1, intact protein mass showed that the majority of K4Q mutant purified from E. coli lacked 
the initial methionine together with the proline residue (Fig. 2.3F). The N-terminal Pro-Pro-Lys 
motif was destroyed and the newly formed Pro-Gln-Lys N-terminus was not methylated according 
to the protein intact mass result (Fig. 2.3G). In consistent with intact protein mass result, SAH 
release was not detected by HPLC (Fig. 2.3G, inset). Here we conclude that the Pro-Pro-Lys motif 










Figure 3.3 MS and HPLC analysis of the methylation reaction using OLA1 K4Q mutant 
peptide and protein as substrates.  
All reactions were carried out at 37 ℃. (A) MS and HPLC (inset) analysis of the synthesized 10-residue 
OLA1 K4Q peptide (calculated [M + H]+: 995.5638, detected: 995.5408). (B) Mass spectrum of the reaction 
between 20 μM OLA1 K4Q peptide and 100 μM SAM (calculated [M + H]+: 995.5638, detected : 
995.5656). (C) Mass spectrum of the reaction between 20 μM OLA1 K4Q peptide and 100 μM SAM in the 
presence of 1 μM NTMT1 (calculated [M + H]+: 995.5638, detected: 995.5667). (D) HPLC monitoring of 
SAH release for the reaction between 40 μM of OLA1 K4Q peptide and 100 μM of SAM in the presence 
of 1 μM NTMT1 at different time intervals. (E) Comparison of the initial rates for SAH release between 
OLA1 and OLA1 K4Q peptides. (F) Intact protein mass of OLA1 K4Q mutant (calculated MW for deletion 
of initial methionine and proline [OLA1K4Q - MP]: 45580.34 Da, detected MW: 45580.2 Da; calculated 
MW for deletion of initial methionine [OLA1K4Q - M]: 45677.45 Da, detected MW: 45676.86 Da). (G) 
Intact protein mass of methylation assay using OLA1 K4Q mutant as substrate (detected MW: 45580.35 
Da & 45677 Da) and SAH release monitored by HPLC (inset). 
 
 3.2.4 Investigation of OLA1 methylation in human cells 
As OLA1 can be methylated by NTMT1 at peptide and protein level in vitro, we continued to 
ask whether it could be methylated in vivo. To test this, the open reading frame of OLA1 was 
inserted into the modified pEGFP-n1 vector which contains a C-terminal Flag tag. The newly 
constructed plasmid was transfected to HEK293FT cells and the Flag-tagged protein was purified 
using anti-Flag M2 magnetic beads (Fig. 3.4D). Protein band for OLA1-EGFP-Flag (~ 73 kDa) 
was excised, in-gel digested by chymotrypsin, and subsequently analyzed by LC-MS. MS raw data 
were analyzed and mapped to the primary sequence of protein OLA1-EGFP-Flag by 
BiopharmaLynx and numerous peptides derived from this protein were identified with a sequence 
coverage of 78.4%. Among them, the N-terminal peptide PPKKGGDGIKPPPIIGRF was not 
detected, but instead, its dimethylated form was heavily found (Fig. 3.4A, retention time: 20.1 
min). The LC-MS results indicated that the first methionine was removed in human cells and nearly 
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all the OLA1 detected were dimethylated. Peptide fragmentations were analyzed manually, and 
many b-ions and y-ions were identified, confirming that OLA1 is N-terminal methylated in human 
cells (Fig. 3.4A). 
Next, we determined whether this modification was catalyzed by NTMT1 in vivo. Previous 
studies applied siRNA knockdown technique to reduce the expression level of NTMT1, and LC-
MS/MS was used to quantify the declined methylation level of its substrates (e.g., DDB2, 
PARP3)29, 33. To avoid this semiquantitative method, HEK293FT NTMT1 gene KO cell line was 
generated using CRISPR-Cas9 (Chapter 2)34. Plasmid pEGFP-n1-OLA1-EGFP-Flag was 
transfected to this NTMT1 KO cell line and the Flag-tagged protein was purified and analyzed as 
previously described. On the contrary to wt HEK293FT cell line, dimethylated N-terminal peptide 
PPKKGGDGIKPPPIIGRF was not detected by LC-MS. Instead, the unmodified N-terminal 
peptide was found (Fig. 3.4B, retention time: 20.0 min). Peptide fragmentation confirmed that 
OLA1 was not methylated in NTMT1 KO cells (Fig. 3.4B). These results demonstrate that OLA1 
is dimethylated in human cell line and NTMT is required for catalyzing this modification. 
Moreover, to verify whether Pro-Pro-Lys motif is important for its in vivo methylation, plasmid 
pEGFP-n1-OLA1K4Q-EGFP-Flag was constructed and transfected to unedited HEK293FT cell 
line. Flag-tagged protein was treated the same way as previously described and only the 
unmethylated N-terminal peptide of OLA1K4Q mutant (Fig. 3.4C, retention time: 21.8 min) was 
identified by LC-MS analysis. Our results indicate that Pro-Pro-Lys especially the lysine residue 
is critical for OLA1 methylation in vitro and in vivo. The K4Q mutant would be a good control for 
studying the functions of OLA1 N-terminal methylation. 
To verify whether NTMT1 would methylate endogenous OLA1, we wanted to generate an 
antibody which specifically recognizes the methylated OLA1. Here, we synthesized the N-methyl-
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L-proline and stachydrine (characterized by 1H and 13C NMR shown in Appendix A), which can 
be used to synthesize the N-terminal OLA1 peptides with methylated prolines as antigens for 








Figure 3.4 LC-MS analysis of OLA1 N-terminal methylation in HEK293FT cells.  
(A) MSE spectrum of mapping the N-terminal peptide of wt OLA-EGFP-Flag expressed in unedited 
HEK293FT cell line (calculated precursor ion: 1902.1324, detected: 1902.1068). (B) MSE spectrum of 
mapping the N-terminal peptide of wt OLA-EGFP-Flag expressed in NTMT1 KO HEK293FT cell line 
(calculated precursor ion: 1874.1011, detected: 1874.0739). (C) MSE spectrum of mapping the N-terminal 
peptide of OLA1K4Q-EGFP-Flag expressed in unedited HEK293FT cell line (calculated precursor ion: 
1874.0647, detected: 1874.0394). (D) SDS-PAGE of FLAG tagged proteins purified using anti-Flag M2 
magnetic beads (1: wt OLA-EGFP-Flag expressed in unedited HEK293FT cell line; 2: OLA1K4Q-EGFP-
Flag expressed in unedited HEK293FT cell line; 3: wt OLA1-EGFP-Flag expressed in NTMT1 KO 
HEK293FT cell line). 
 
 3.2.5 N-terminal methylation of OLA1 does not alter its ATPase and GTPase 
activity in vitro 
OLA1 belongs to the family of GTPases but was reported to function as an ATPase9-10. Here 
we determined whether the N-terminal methylation of OLA1 would affect or alter its catalytic 
activity. Dimethylated OLA1 was obtained by incubating OLA1 with SAM in the presence of 
NTMT1. As a control, OLA1 was incubated with SAM in the absence of NTMT1. SAM and SAH 
100 
were removed by gel filtration. Dimethylated OLA1 was further confirmed by intact protein mass 
(Fig. 3.5A & 3.5B). 
The hydrolysis of ATP and GTP were measured by HPLC, and adenosine was added as an 
external standard (retention time: 6.6 min). The retention times for standards (ATP, ADP, AMP, 
GTP, GDP, GMP) were shown in Fig. 3.5C & 3.5D. The hydrolysis of ATP in the absence of 
OLA1 was slow (0.05 µM/min, Fig. 3.5E, 3.5L & 3.5M). As expected, both OLA1 and 
dimethylated OLA1 were able to catalyze the hydrolysis of ATP with high activities, however, the 
reaction rates were undistinguishable from each other (1.51 µM/min for OLA1, 1.52 µM/min for 
Me2-OLA1, Fig. 3.5F, 3.5G, 3.5L & 3.5M). We observed two products, ADP and AMP, for ATP 
hydrolysis. ADP was previously reported as the only product9. To confirm that OLA1 can 
hydrolyze ADP as well, we performed an ADP hydrolysis assay. Our results showed that both 








Figure 3.5 HPLC-based ATPase and GTPase assay for OLA1 and dimethylated OLA1.  
All the reactions were carried out at 37 ℃. (A) Intact protein mass of OLA1 after incubating with SAM. 
(B) Intact protein mass of dimethylated OLA1. (C) HPLC analysis of ATP (retention time: 12.9 min), ADP 
(retention time: 10.7 min) and AMP (retention time: 8.2 min) standards. (D) HPLC analysis of GTP (11.5 
min), GDP (retention time: 9.1 min) and GMP (retention time: 6.6 min) standards. (E) HPLC monitoring 
of ATP (125 µM) hydrolysis in the absence of OLA1 at different time intervals. (F) HPLC monitoring of 
ATP (125 µM) hydrolysis in the presence of 5 µM OLA1 at different time intervals. (G) HPLC monitoring 
of ATP (125 µM) hydrolysis in the presence of 5 µM dimethylated OLA1 at different time intervals. (H) 
HPLC monitoring of ADP (125 µM) hydrolysis with OLA1, dimethylated OLA1 or without OLA1. The 
reactions were carried out for 1 h. (I) HPLC monitoring of GTP (125 µM) hydrolysis in the absence of 
OLA1 at different time intervals. (J) HPLC monitoring of GTP (125 µM) hydrolysis in the presence of 5 
µM OLA1 at different time intervals. (K) HPLC monitoring of GTP (125 µM) hydrolysis in the presence 
of 5 µM dimethylated OLA1 at different time intervals. (L) Comparison of the products formation for 
ATP/GTP hydrolysis with OLA1, dimethylated OLA1 or without OLA1. (M) Comparison of the initial 
reaction rates for ATP/GTP hydrolysis with OLA1, dimethylated OLA1 or without OLA1. 
 
Next, we examined the GTPase activity of OLA1 (Fig. 3.5I, 3.5J & 3.5K). Note that the GTP 
often contains contaminative GDP, and our batch contained ~18% of GDP (quantified by HPLC). 
Thus, the GDP background was subtracted for calculating the initial reaction rates (Fig. 3.5L 
&3.5M). OLA1 was able to hydrolyze GTP (0.25 μM/min) but the reaction rate was much lower 
compared to ATP (1.51 μM/min). These results are in consistent with previous reports by Koller-
Eichhorn et al. and Sun et al. but are on the contrary to the one published by Chen et al.1, 10, 15 Chen 
et al. reported that the GTPase activity of OLA1 was ~ 7-fold higher than ATPase activity by 
measuring the release of [32P] Pi15. Both the radiolabeled assay and HPLC-based assay were 
performed in vitro, and our HPLC results clearly showed that the ATP hydrolysis rate was much 
faster than the rate of GTP hydrolysis. 
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Taken together, both OLA1 and its dimethylated form exhibit a higher activity for ATP 
hydrolysis than GTP hydrolysis. Moreover, OLA1 can further hydrolyze ADP to form AMP. 
However, the N-terminal methylation of OLA1 has no influence on its ATPase or GTPase activity 
in vitro. The flexible N-terminus of OLA1 was not seen in the crystal structure (PDB: 2OHF) and 
may be not involved in the ATP/GTP binding site, which explains why its methylation has no 
effect on its catalytic activity.  
 3.2.6 Knockout of OLA1 in HEK293FT and HCT116  
To eliminate the influences of endogenous OLA1 for the study of N-terminal methylation in 
human cell lines, OLA1 was knocked out in HEK293FT cell line and colon cancer cell line 
HCT116 using CRISPR-cas9 system. OLA1 gene KO cells were confirmed by western blot (Fig. 
3.6A & 3.6B) and DNA sequencing (Fig. 3.6C & 3.6D). 
Till now, the functions of OLA1 N-terminal methylation remain unknown. Previous study 
indicated that OLA1 regulates centrosome amplification and cell growth11-12, 22. To test whether 
its N-terminal methylation would participate in such regulations, plasmids pEGFP-n1-OLA1-
EGFP-Flag and pEGFP-n1-OLA1K4Q-EGFP-Flag (production of methylation deficient OLA1) 
were transfected into OLA1 KO HCT116 cell line. However, the transfection efficiency was very 







Figure 3.6 OLA1 gene knockout using CRISPR-Cas9 system.  
(A) Western blot analysis of OLA1 KO cell lines (HEK293FT & HCT116) using rabbit anti-OLA1 
antibody. (B) Western blot analysis of actin as a loading control for OLA1 KO cell lines (HEK293FT & 
HCT116). (C) DNA sequencing result of OLA1 KO HEK293FT cell line. (D) DNA sequencing result of 
OLA1 KO HCT116 cell line. 
 
 3.2.7 Methylation of overexpressed OLA1-EGFP-Flag does not alter its subcellular 
location 
OLA1 was previously reported to exhibit a nucleocytoplasmic distribution and may shuttle 
between cytoplasm and nucleus10. Cai et al. reported that N-terminal trimethylation of DDB2 
would promote its nuclear localization while the methylation deficient mutant displayed a reduced 
distribution in cell nuclear fraction29. Here, we wanted to test whether the N-terminal methylation 
would affect the subcellular distribution of OLA1. Plasmids pEGFP-n1-OLA1-EGFP-Flag, 
pEGFP-n1-OLA1K4Q-EGFP-Flag and pEGFP-n1 empty vector were transfected into OLA1 KO 
HEK293FT cells and the green fluorescence signal was visualized by confocal microscopy. The 
dimethylated OLA1 and the unmodified OLA1 K4Q mutant expressed in HEK293FT OLA1 KO 
cells were confirmed by protein in-gel digestion and LC-MS analysis (See Appendix C). Majority 
of OLA1-EGFP and OLA1K4Q-EGFP were localized in cytoplasm. EGFP, as a control, was 
distributed in both nucleus and cytoplasm. Taken together, the subcellular location of 
overexpressed OLA1 was not affected by its N-terminal methylation. This result suggests that the 





Figure 3.7 Comparison of the subcellular location of OLA1 and K4Q mutant using confocal 
microscopy.  
Plasmids pEGFP-n1-OLA1-EGFP-Flag, pEGFP-n1-OLA1K4Q-EGFP-Flag and pEGFP-n1 empty vector 
were transfected into OLA1 KO HEK293FT cells. OLA1 and EGFP proteins were imaged by green 
fluorescence. Cell nucleus was stained with DAPI.  
 
 3.3 Materials and methods 
 3.3.1 Cell culture conditions 
Human embryonic kidney (HEK) 293FT cells (generous gift from Dr. Yulan Xiong) were 
cultured in DMEM (with 4.5 g/L glucose, L-glutamine & sodium pyruvate, Corning cellgro) 
supplemented with 10% FBS (heat inactivated FBS, Gibco) and 1% P/S (Gibco) in a humidified 
atmosphere containing 5% CO2 at 37 C. Human colorectal carcinoma cell line HCT116 (generous 
gift from Dr. Ryan Rafferty) were cultured in McCoy’s 5a Modified Medium (Corning cellgro) 
supplemented with 10% FBS and 1% P/S in a humidified atmosphere containing 5% CO2 at 37 C.  
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 3.3.2 Plasmids construction 
Plasmid pET28-MHL-NTMT1 was constructed as previously described. The open reading 
frame of human OLA1 was amplified from HEK293FT cDNA to introduce NdeI and XhoI 
restriction sites, and subcloned into E. coli expression vector pET30a (+) (Novagen) to generate 
plasmid pET30a-OLA1-His6. Plasmid pET30a-OLA1K4Q-His6 was constructed similarly, except 
that the forward primer contained a K4Q mutation site. Mammalian expression vector pEGFP-n1 
was modified to introduce a FLAG epitope tag (DYKDDDDK) at the C terminus of EGFP. To 
express wt OLA1 and K4Q mutant in mammalian cells, their coding sequences were cloned and 
inserted into the modified pEGFP-n1-Flag vector with XhoI and BanHI restriction sites. Plasmids 
for OLA1 knockout using the CRISPR-Cas9 system were constructed similarly to the one 
described in chapter 234. Briefly, the guide sequences were designed based on an online CRISPR 
Design Tool (http://tools.genome-engineering.org) established by Dr. Zhang group34. The 
designed oligos were annealed to give sticky BbsI ends and inserted into vctor PX459 (generous 
gift from Dr. Yulan Xiong) linearized by BbsI. All the constructed plasmids were confirmed by 










Table 3.1 Primer sequences for plasmids construction. 





















































 3.3.3 Expression and purification of recombinant proteins 
His6-NTMT1 was expressed and purified as previously described (Chapter 2). Protein OLA1-
His6 and its K4Q mutant were expressed in E. coli. BL21 (DE3) (Lucigen). Bacteria were grown 
in 2 L of LB medium supplemented with 50 µg/mL kanamycin. When OD600 nm reached to 0.6 - 
0.8, IPTG was added to a final concentration of 0.4 mM to induce protein expression. Bacteria 
were grown at 18 C for an additional 18 h and then harvested by centrifugation at 5,000 × g for 
20 min at 4C. Bacterial pellets were collected and stored at −80 C until further use. 
Composition and pH values of buffers used in this study are summarized in Table 3.2. Proteins 
were purified following a modified procedure in a published literature9. Cell pellets were re-
suspended in buffer A and lysed by sonication for 15 min (5-second on and 3-second off) at 40% 
amplitude. The cell debris was removed by centrifugation at 18,000 × g for 45 min. The 
supernatant was decanted and incubated with Ni-NTA resin (Qiagen) that had been pre-
equilibrated with buffer A for 30 min. The resin was washed with 30 column volumes of buffer B 
and then eluted with 5 column volumes of buffer C. Fractions containing the targeted protein were 
combined and protein was exchanged into buffer D using a HiPrepTM 26/10 desalting column (GE 
Healthcare). The purified proteins were concentrated to 10−50 mg/ml and stored in aliquots at −80 
C until further use. Protein purity was assessed by 12% tris-glycine SDS-PAGE and their 







Table 3.2 Ingredients of buffers.  
Buffer Composition 
A 50 mM Tris (pH7.9), 700 mM NaCl, 5 mM MgCl2 and 10% glycerol 
B 50 mM Tris (pH 7.9), 100 mM NaCl, 5 mM MgCl2, 5% glycerol and 40 mM 
Imidazole 
C 50 mM Tris (pH 7.9), 100 mM NaCl, 5 mM MgCl2, 5% glycerol and 250 mM 
Imidazole 
D 50 mM Tris (pH7.9), 100 mM NaCl 
E 25 mM Tris (pH 7.5), 50 mM KCl   
F 1 × PBS (pH 7.4), 0.2% Triton X-100 
G 500 mM Tris (pH7.9), 10% SDS, 20 mM TCEP 
H 100 mM Tris (pH 7.9), 100 mM iodoacetamide,  
I 100 mM Tris (pH 7.9), 10 mM CaCl2 
J 50 mM Tris (pH 7.5), 200 mM NaCl, 5 mM MgCl2 
 
 3.3.4 Peptide synthesis 
Peptide analogs of N-terminal wt OLA1 [PPKKGGDGIK(CONH2)] and OLA1 K4Q mutant 
[PPQKGGDGIK(CONH2)] were synthesized on Rink amide resins (Peptides International) using 
standard Fmoc chemistry as previously described35. The synthesized peptides were purified by 
HPLC and their purities and identities were confirmed by HPLC and LC-MS, respectively. 








Table 3.3 HPLC conditions for peptide purification and characterization.   
 Semi-preparative HPLC Analytical HPLC 
Column Luna C18(2), 5 m, 100 
Å, 10  250 mm 
(Phenomenex) 
XBridge BEH Shield RP 18, 5 m, 
130 Å, 4.6  250 mm (Waters) 
Flow Rate 3.0 mL/min 1.0 mL/min 













0−25 min: 5-40%; 25−30 
min: 40-90% 
(11.9 min) 







0−30 min: 5-15%; 30-50 
min: 15-50% 
(37.0 min) 
0-30 min: 5−15%; 30-35 min: 15-
70% 
 (10.8 min) 
 
 
 3.3.5 HPLC and MS-based in vitro methylation assay 
Methylation of OLA1 at peptide and protein levels by wt NTMT1 and SAM was investigated 
using LC-MS and HPLC. For LC-MS analysis, 20 μM OLA1 peptides or proteins in 10 mM 
ammonium bicarbonate (ABC), 200 μM SAM, and 1 μM wt NTMT1 were incubated at 37 C for 
30 min. Negative controls were performed in the absence of wt NTMT1. The peptide reaction 
mixtures were quenched with equal volume of water containing 0.1% formic acid and then 
analyzed by LC-MS. The protein reaction mixtures were not quenched and directly analyzed by 
intact protein mass, which was performed on a C4 analytical column eluted at a flow rate of 0.4 
ml/min. Mobile phases A and B consisted of 0.1% formic acid in water and in acetonitrile, 
respectively. The gradient is: 0−1 min, 5% B; 1−3.5 min, 5−100% B; and 3.5−4.7 min, 100% B. 
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Elution from 2−4.7 min was injected into the mass spectrometer, which was operated in a MS 
positive mode. Raw data was processed by MassLynx (Waters) and BiopharmaLynx (Waters).  
SAH release was monitored by HPLC and adenosine was added as an external standard to 
quantify SAH. Experiments were carried out in the following way. In a final volume of 400 μL, 1 
μM wt NTMT1 was added to the mixture of 100 μM SAM and 40 μM OLA1 peptides at 37 C in 
buffer E. Aliquots of 40 μL were withdrawn at selected time intervals (1 to 90 min) and quenched 
with 40 μL of 0.4% TFA solution containing 4 μM adenosine. After centrifugation at 18,000 g for 
2 min, 50 μL of the supernatant was injected into an XBridge Shield RP 18 column (3.5 μm, 130 
Å, 4.6 mm × 150 mm, Waters). The column was eluted at 1 mL/min with an isocratic gradient of 
1% methanol in water supplemented with 0.01% TFA. Concentrations of SAH were determined 
by A260 nm ratios of the peak areas corresponding to SAH and adenosine.  
 3.3.6 Mass spectrometric analysis of Flag tagged OLA1 proteins purified from 
human cells 
HEK293FT and HEK293FT NTMT1 KO cells were grown in 175 cm2 flasks at 37℃ in 
DMEM medium supplemented with 10% FBS and 100 U/ml P/S in a humidified atmosphere 
containing 5% CO2. At 70-90% confluence stage, cells were transfected with 20 μg plasmid 
pEGFP-n1-OLA1-EGFP-Flag or pEGFP-n1-OLA1K4Q-EGFP-Flag using transfection reagent 
Lipo D293 (SignaGen Laboratories). After 36 h, cells were harvested, suspended in 3 ml of 1× 
PBS (pH 7.4) buffer and lysed by sonication for 4 min (5-second on and 3-second off) at 40% 
amplitude. The cell debris was removed by centrifugation at 15,000 × g for 15 min and the 
supernatant was incubated with 30 μl Flag M2 magnetic beads (Sigma) for 4 h at 4 ℃. After 
washing with buffer F for three times, Flag tagged proteins were eluted with 60 μl of 200 mM 
glycine (pH 2.5). The pH of the eluted samples was adjusted to ~7 using 1 M Tris (pH 7.9). Proteins 
114 
were reduced by 6 μl buffer G for 10 min at 37 ℃ and alkylated with buffer H for 15 min at 37℃36. 
Protein samples were concentrated to ~ 10 μl by speed-vac, mixed with 10 μl of 2 × Laemmli 
sample (Bio-Rad) buffer and heated at 100 ℃ for 5 min before loading to SDS-PAGE. After 
staining and destaining, bands of OLA1-EGFP-Flag or OLA1K4Q-EGFP-Flag (~73kD) were 
excised, cut into small pieces and washed with 100 mM ammonium bicarbonate 
(ABC)/acetonitrile (1:1, vol/vol) at 37 ℃ to completely destain the gel. After shrinking and 
dehydrating with acetonitrile, gel pieces were incubated with chymotrypsin (Promega, 200 ng 
diluted in buffer I) for 18 h at 25 ℃. Digestion products were extracted with 100 μl of 5% formic 
acid, 100 μl of 100% acetonitrile/10% formic acid (1:1, vol/vol), and 100 μl of pure acetonitrile, 
respectively. Samples were concentrated by speed-vac, filtered with Ultrafree PTFE membrane 
(Millipore) and injected to an M class UPLC-XEVO G2-XS QTof (Waters) equipment. Protein 
digestion products were firstly cleaned using a trapping column (ACQUITY UPLC M-Class 
Symmetry C18 Trap Column, 100 Å, 5 µm, 300 µm × 50 mm, Waters) and separated on an 
analytical column (ACQUITY UPLC M-Class HSS T3 Column, 1.8 µm, 300 µm × 100 mm, 
Waters) with a flow rate of 8 ul/min. Mobile phase A and B consisted of 0.1% formic acid in water 
and acetonitrile, respectively. The gradient for separation is 1 % to 40 % of mobile phase B for 
40min. The mass spectrometer was operated in positive polarity, sensitivity mode, and MSE mode 
with a ramp collision energy ranging from 20 to 45 V. All data were mapped to the primary 
structure of target proteins by BiopharmaLynx (Waters) and peptide fragmentations were analyzed 
manually. 
 3.3.7 HPLC-based ATPase and GTPase assay 
The dimethylated OLA1 was produced by incubating OLA1 (20 μM) purified from E. coli 
with SAM (200 μM) and NTMT1 (3 μM) at 37 ℃ for 45 min in buffer E. Proteins were desalted 
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into buffer J using a HiPrepTM 26/10 desalting column (GE Healthcare). Dimethylated proteins 
were concentrated and confirmed by intact protein mass. Protein concentrations were determined 
by bicinchoninic acid assays (BCA, ThermoFisher) using a BSA calibration curve. 
The ATP/GTP hydrolysis was monitored by HPLC and adenosine was added as an external 
standard to quantify the formation of products ADP/AMP/GDP. Experiments were carried out in 
the following way. In a final volume of 400 μL, 5 μM OLA1 or dimethylated OLA1 were incubated 
with 125 μM ATP/GTP at 37 C in buffer J. Aliquots of 60 μL were withdrawn at selected time 
intervals (5 to 80 min) and quenched with 60 μL of 0.2% TFA solution containing 50 μM 
adenosine. After centrifugation at 18,000 × g for 2 min, 50 μL of the supernatant were injected 
into an XBridge Shield RP 18 column (3.5 μm, 130 Å, 4.6 × 250 mm, Waters). Mobile phase A 
consisted of 10 mM potassium phosphate buffer (pH 6.5) supplemented with 5 mM 
tetrabutylammonium bromide (Chem-Impex) and mobile B consisted of 10 mM potassium 
phosphate buffer (pH 6.5)/ methanol (3/2 vol/vol) supplemented with 5 mM tetrabutylammonium 
bromide9. The gradient for separation is 20 % to 100 % of mobile phase B for 15 min with a flow 
rate of 1ml/min. Concentrations of SAH were determined by A260 nm ratios of the peak areas 
corresponding to ADP/AMP/GDP and adenosine. Measurements were performed in duplicate. 
 3.3.8 OLA1 knockout using CRISPR-Cas9 system 
Procedures for OLA1 gene KO in HEK293FT cell line and HCT116 cell line were similar to 
the one described in Chapter 234. Briefly, 0.5 μg of plasmids PX459-OLA1sgRNA1 and 0.5 μg of 
PX459-OLA1sgRNA2, or 0.5 μg of plasmids PX459-OLA1sgRNA3 and 0.5 μg of PX459-OLA1sgRNA4 
were mixed and transfected into HEK293FT seeded in a 6-well plate using transfection reagent 
LipoD293 (SignaGen Laboratories) and Opti-MEM® I Reduced Serum Medium (ThermoFisher) 
when cell confluency reached to 50%-70%. For HCT116 cell line, plasmids were transfected with 
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lipofectamine 2000 (ThermoFisher). After 36h, cells were treated with 3 μg/ml of puromycin for 
3 days. Cells were then dissociated with TrypLE™ Express Enzyme (ThermoFisher), counted and 
serially diluted in DMEM medium (for HEK293FT) or McCoy’s 5a Modified Medium (for 
HCT116) supplemented with 20% FBS to a final cell density of 50-100 cells per 15 ml medium. 
The diluted cells were plated to two 96-well plates and cultured for 2 weeks. After passaging to 
24-well pate, cells were screened by western blot using anti-OLA1 antibody (Bethyl). After 
confirmed by DNA sequencing, the OLA1 KO cell lines were frozen in liquid N2. 
 3.3.9 Western blot 
Equal volumes of cell lysates were separated in a 12% tris-glycine SDS-PAGE and then 
transferred to a supported nitrocellulose membrane (Bio-Rad). The membranes were incubated 
with rabbit anti-OLA1 antibody (1:1000) overnight at 4 C. After washing with TBS-T buffer, 
membranes for were incubated with goat anti-rabbit antibody (1:5000) by gentle shaking for 1 h 
at room temperature. Upon similar washing, bands were detected using SuperSignal West Pico 
PLUS chemiluminescent substrate (Thermo Fisher Scientific) following manufacturer’s protocol. 
The bands were visualized using Amersham Imager 600 (GE Healthcare). 
 3.3.10 Subcellular location of overexpressed OLA1 observed by confocal 
microscopy 
HEK293FT OLA1 KO cells were seeded on glass coverslips coated with poly-L-ornithine 
hydrobromide (Sigma) and transfected with plasmid pEGFP-n1-OLA1-EGFP-Flag, pEGFP-n1-
OLA1K4Q-EGFP-Flag or empty vector pEGFP-n1 using transfection reagent Lipo D293 (SignaGen 
Laboratories). After 36 h, cells were fixed with 4% paraformaldehyde (PFA) in 1 × PBS for 20min. 
Cell nuclei were stained with 4’,6-diamidino-2-phenylindole (DAPI). All confocal images were 
acquired on a Carl Zeiss 700 microscope. 
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 3.3.11 Synthesis of N-methyl-L-proline and stachydrine 
Procedure for the synthesis of N-methyl-L-proline was similar to the published literature37. 
Briefly, 37% formaldehyde (1.6 ml, 19.7 mmol) was added to the methanol solution containing L-
proline (2g, 17.4 mmol). 10% palladium on carbon (Pd/C, 500mg) was added to the mixture and 
the resulting slurry was stirred in a hydrogen atmosphere (27 psi) overnight. The Pd/C catalyst was 
removed by filtering through a Celite pad. The Celite pad was washed with methanol and the 
filtrates were concentrated under reduced pressure. The residues were re-dissolved in methanol 
and concentrated a second time to give a solid, which was recrystallized with methanol-diethyl 
ether to provide fine needles (2.14 g, 95% yield). 1H NMR (600 MHz, D2O) δ 3.85 (m, 1H), 3.69 
(m, 1H), 3.11 (m, 1H), 2.88 (s, 3H), 2.53 -2.38 (m, 1H), 2.11 (m, 1H), 2.08 - 2.00 (m, 1H), 1.99 - 
1.90 (m, 1H). 13C NMR (151 MHz, D2O) δ 173.65, 70.49, 56.19, 40.56, 28.69, 22.72. 
Stachydrine was synthesized with a modified procedure of the published literature38. Briefly, 
in a 300 ml round bottom flask, L-proline (2 g, 17.4 mmol) was dissolved in 45 ml NaOH solution 
(2 M). Dimethyl sulfate (4.12 ml, 43.4 mmol) was added to the solution drop by drop. The mixture 
was stirred at 45 ℃ for 4 h. The reaction was quenched by adding 20 ml of NaOH solution (12M) 
and refluxed at 100 ℃ for 2 h. After cooling down, the pH was adjusted to ~2 using concentrated 
HCl. Water was removed under reduced pressure and the residues were extracted with ethanol. 
After removing ethanol by reduced pressure, the residues were dissolved in 25 ml water and 
incubated with 20 g of IRA 402 hydroxide resin (Amberlite). The flow through were concentrated 
under reduced pressure and the residues were taken up by ethanol. Removing of ethanol under 
reduced pressure provided a white solid (2.43 g, 78% yield). 1H NMR (600 MHz, D2O) δ 4.30 (m, 
1H), 3.71 (m, 1H), 3.56 (m, 1H), 3.30 (s, 3H), 3.10 (s, 3H), 2.52 (m, 1H), 2.44 - 2.28 (m, 1H), 2.27 
- 2.02 (m, 2H). 13C NMR (151 MHz, D2O) δ 169.18, 74.31, 67.70, 52.11, 46.05, 24.55, 18.47. 
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Chapter 4 - Conclusions and future perspectives 
 4.1 Conclusions 
Here, an activity-based substrate profiling strategy was performed to uncover the potential 
targets of NTMT1. For proof of concept, Hey-SAM, as a SAM surrogate containing a terminal 
alkynyl group, was able to alkylate RCC1 protein with a high efficiency in the presence of wt 
NTMT1. Cu(I) catalyzed click chemistry was then performed to label the alkylated RCC1 with a 
biotin group which allowed its purification using streptavidin beads.  
The profiling strategy was applied to identify NTMT1 substrates from human cell lysates. 
NTMT1 was knocked out in HEK293FT cell line by CRISPR-cas9 which resulted in the 
production of hypomethylated NTMT1 substrates. After alkylation using Hey-SAM and click 
chemistry, the biotin labelled proteins were enriched by streptavidin beads, separated on SDS-
PAGE, digested by trypsin and analyzed by LC-MS. The statistical analysis of identified and 
quantified proteins together with the protein N-terminal motif analysis identified 70 proteins as 
putative NTMT1 targets. Among them, three of the previous confirmed NTMT1 substrates 
including RCC1, SET and RL23A were included. Target validation confirmed that N-terminal 
peptide of PB1, N-terminal peptide of SPD2B, protein RS14 and protein OLA1 were NTMT1 
substrates in vitro. 
In addition, the in vivo investigation of OLA1 N-terminal methylation was carried out in 
normal and NTMT1 KO cells. Overexpressed OLA1 protein in normal HEK293FT was 
dimethylated and this modification was absent in NTMT1 KO cells. These results confirm that 
NTMT1 is the enzyme for catalyzing the N-terminal methylation of OLA1 in human cells. 
Moreover, our preliminary study reveals that N-terminal methylation of OLA1 does not alter its 
ATPase activity and subcellular location.  
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 4.2 Merits and limitations 
As previously reported, lots of protein lysine and arginine methyltransferases (e.g., PRMT1, 
PRMT3, EuHMT1, EuHMT2) cannot utilize the bulky SAM analogs (e.g., Hey-SAM)1-2. To 
perform activity-based substrate profiling assay, protein engineering is usually required. One 
drawback of protein engineering is that the mutants may have different substrate specificity 
compared to wt enzyme. Here, we reported that a bulky SAM surrogate, Hey-SAM, was able to 
be taken by wt NTMT1 as a cofactor, which avoided the time-consuming protein engineering.  In 
addition, NTMT1 knockout cells were generated to specifically produce the hypomethylated 
NTMT1 substrates. Previously reported method for inducing hypomethylated proteins relies on 
Adox, an inhibitor of SAH hydrolase, which is not specific. One concern for our approach is that 
NTMT2, the reported monomethyltransferase, might have the potential to monomethylate the 
endogenous NTMT1 substrates. However, none of its physiological substrates were confirmed so 
far. Moreover, monomethylated OLA1-EGFP-Flag was not observed in NTMT1 KO cells 
according to our LC-MS results, which demonstrated that NTMT2 might have very low or no 
activity towards OLA1 in human cells. These results indicate that it is feasible to generate 
hypomethylated NTMT1 substrates using NTMT1 KO cells. Another strength of our approach is 
the application of statistics and motif analysis in substrates identification, which narrows down the 
number of potential targets and points to the biologically meaningful substrates. 
Despite that 70 proteins were identified as putative NTMT1 substrates, not all of the known 
substrates (e.g., DDB2, PARP3) were included3-4. Possible reasons include that some proteins may 
have very low expression level and some proteins were not properly labeled. Moreover, target 
validation showed that the identified NTMT1 putative targets contain some false positive proteins 
(e.g., H2A1B, DDX60L). This may be caused by the nonspecific labeling and high expression 
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level of some housekeeping proteins. Though motif analysis can eliminate partial of the false 
positive protein, further improvements (e.g., higher labeling efficiency, lower nonspecific binding) 
and novel approach are necessary to solve this challenging issue for MS-based protein 
identification. 
 4.3 Future perspectives 
As protein N-terminal methylation plays important roles in mitosis and DNA damage repair, 
and dysregulation of NTMT1 promotes the growth and metastasis potential of cancer cells, it 
would be important to elucidate the function of N-terminal methylation by uncovering substrates 
of NTMT1. Here, our activity-based substrate profiling approach uncovered several new 
substrates, however, it has its intrinsic limitations. For future perspectives, it is important to exploit 
new strategies to identify more of the true substrates.  
Jakobsson et al. reported an HRMS-based substrate profiling approach for METTL13-N5. In 
this method, proteins were labelled using SILAC for better quantification, and the corresponding 
enzyme METTL13 was knocked out5. Proteins obtained from normal and METTL13 KO cell 
lysates which contained the methylation sites were identified, quantified and compared5. 
Application of this method requires two prerequisites. First, substrates should be modified 
specifically by the target enzyme and the enzyme KO would abolish the modification. Second, a 
high-resolution mass spectrometry is required for precise protein identification and quantification.  
Hu et al. reported a strategy to profile substrates of O-linked β-N-acetylglucosamine 
transferase (OGT) using electrophilic probes6. This strategy provides some hints on eliminating 
the nonspecific protein labeling. The electrophilic probes containing an allyl halide group (e.g., 
allyl bromide, allyl chloride) bind to OGT and react with the adjacent cysteine to form a covalent 
bond6. After group transfer reaction catalyzed by OGT, the substrates were covalently attached to 
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the complex of OGT and the probe6. His6-tagged OGT could be purified by Ni-NTA resin and its 
substrates would be pulled-down together as well6. This strategy is very specific as only the true 
substrates can form a complex with the target enzyme. A proposed strategy for profiling NTMT1 
targets using an electrophilic SAM analog is shown in Fig 4.1. NTMT1 should be engineered to 
introduce a cysteine residue in the SAM binding pocket to react with the electrophilic SAM analog. 
However, several limitations should be considered before performing this approach. First, the 
electrophilic probe is very reactive and may react with some surface residues (e.g., cysteine), which 
will result in nonspecific labeling. Second, the probe is not stable in basic condition and it would 
a challenge for enzyme to work in a weak acid solution. Third, the mechanism for methylation 
reaction is SN2, and the steric hindrance generated by the NTMT1-probe complex might slow 
down the reaction. Therefore, it would be important to optimize the probe and engineer NTMT1. 
 
 
Figure 4.1 Proposed strategy for NTMT1 substrates profiling using an electrophilic probe. 
 
Another future perspective is to elucidate the function of OLA1 N-terminal methylation. 
Profiling the methylation readers will be a good start point. In chapter 1, several methods for 
methylation reader profiling including immunoprecipitation, photo-affinity crosslinking and yeast 
three-hybrid system have been reviewed. It will be necessary to try these methods to uncover the 
methylation readers. Moreover, it is worthwhile to test the existence of protein N-terminal 
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demethylase by performing a demethylase assay. All these studies will help us understand this 
important N-terminal methylation. 
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Appendix B - Candidate substrates of NTMT1 
The previously identified NTMT1 substrates were highlighted with yellow color; the validated targets either 
at peptide level or at protein level are highlighted with green color. Note: protein subcellular distributions 
are assigned based on UniProt database and some of the locations are predicted by similarity. 











P08670 VIM 17 449.57 7.82E-06 2.88 Cytoplasm 
P53396 ACLY 34 439.42 9.73E-05 2.95 Cytoplasm  
Q9NR22 PRMT8  12 289.60 1.34E-05 6.37 
Cell 
membrane  
P54652 HSPA2 4 246.86 0.000118 2.97 Cytoplasm  
P22102 GART  11 173.66 0.000116 2.52 Cytoplasm  
P13667 PDIA4  10 137.95 5.01E-05 2.40 Cytoplasm  
P04181 OAT 13 115.58 8.47E-05 2.88 Cytoplasm  
Q5H9U9 DDX60L 5 92.45 5.94E-05 4.12 Unknown 
Q05BV3 EML5 4 90.08 7.60E-05 3.16 Cytoplasm  
P37802 TAGLN2  5 75.66 0.000104 3.12 Cytoplasm  
P62750 RPL23A 5 70.68 4.02E-05 4.77 Cytoplasm  
Q6GYQ0 RALGAPA1  4 68.95 5.95E-05 2.36 
Cytoplasm, 
nucleus  
Q8N7X0 ADGB  1 64.13 0.002031 2.91 Unknown 
P15121 AKR1B1 2 59.92 2.11E-06 3.15 Cytoplasm  
P42336 PIK3CA 2 58.43 0.000209 4.44 Cytoplasm  
P18754 RCC1 4 56.32 5.01E-05 3.46 
Cytoplasm, 
nucleus  
Q9Y6M1 IGF2BP2  2 50.81 6.73E-05 2.85 
Cytoplasm, 
nucleus  




P61158 ACTR3 4 43.57 0.000311 2.70 
Cytoplasm, 
nucleus  
P35232 PHB 1 43.24 0.001095 3.05 Cytoplasm  
Q659A1 ICE2  2 42.68 0.000314 3.08 Nucleus   
Q6UB35 MTHFD1L  2 42.05 0.00011 2.43 Cytoplasm  
O00160 MYO1F 1 38.42 1.53E-05 7.83 Cytoplasm  
B4DIP2 ERBIN 2 38.40 0.000237 2.79 Unknown 
Q9Y4E1 WASHC2C  2 37.10 0.000257 8.23 Cytoplasm  
Q641Q2 WASHC2A  2 37.10 0.000257 8.23 Cytoplasm  
Q8IYD8 FANCM  4 36.06 0.000281 3.22 Nucleus   
Q9Y5S2 CDC42BPB  3 34.31 2.07E-05 3.44 
Cell 
membrane   
P62263 RPS14  2 34.10 0.000113 4.20 
Cytoplasm, 
nucleus  
Q16576 RBBP7  1 32.22 0.000883 4.23 Nucleus  
Q8NBS9 TXNDC5  2 29.80 0.000341 2.77 Cytoplasm  
Q8TF47 ZFP90  1 29.54 0.000505 2.82 Nucleus  
P04908 HIST1H2AB  1 29.50 0.00172 2.57 Nucleus 
P0C0S8 HIST1H2AG  1 29.50 0.00172 2.57 Nucleus 
P20671 HIST1H2AD  1 29.50 0.00172 2.57 Nucleus 
Q16777 HIST2H2AC 1 29.50 0.00172 2.57 Nucleus 
Q6FI13 HIST2H2AA3  1 29.50 0.00172 2.57 Nucleus 
Q7L7L0 HIST3H2A 1 29.50 0.00172 2.57 Nucleus 
Q93077 HIST1H2AC  1 29.50 0.00172 2.57 Nucleus 
Q96KK5 HIST1H2AH  1 29.50 0.00172 2.57 Nucleus 
Q99878 HIST1H2AJ  1 29.50 0.00172 2.57 Nucleus 
Q9BTM1 H2AFJ 1 29.50 0.00172 2.57 Nucleus 
P16104 H2AFX  1 29.50 0.00172 2.57 Nucleus 
Q8IUE6 HIST2H2AB 1 29.50 0.00172 2.57 Nucleus 
Q96QV6 HIST1H2AA  1 29.50 0.00172 2.57 Nucleus 
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Q9Y2Z9 COQ6  1 26.40 7.67E-05 2.74 Cytoplasm  
P62805 HIST1H4A   1 26.25 0.000414 2.72 Nucleus 
P10606 COX5B 1 26.03 0.000181 4.29 Cytoplasm  
Q8IWG1 WDR63 1 23.87 0.000666 3.67 Cytoplasm  
Q8NB90 SPATA5  2 23.41 7.21E-05 3.09 Cytoplasm  
P46459 NSF 2 21.53 0.000219 2.44 Cytoplasm  
Q01955 COL4A3 2 20.50 7.26E-06 8.67 
Extracellular 
matrix 
Q2PPJ7 RALGAPA2  2 20.03 0.000238 3.61 Cytoplasm  
Q5T5U3 ARHGAP21 2 19.69 1.60E-05 3.01 Cytoplasm  
Q9UQB3 CTNND2  1 17.29 0.004354 2.48 Nucleus  
Q9NTK5 OLA1  1 16.12 0.000527 3.57 
Cytoplasm, 
nucleus  
Q12965 MYO1E  2 15.73 0.000128 2.90 Cytoplasm  
Q86U86 PBRM1  1 15.47 4.33E-06 7.29 Nucleus  
Q9BQ39 DDX50 1 12.22 5.70E-05 2.94 Nucleus 
Q86VW1 
SLC22A16 
OCT6 1 11.67 1.39E-05 3.90 Membrane   
Q6ZRP0 PRR23C 1 11.44 5.58E-06 5.67 Unknown 
Q01105 SET 2 11.44 8.35E-05 4.14 Cytoplasm  
Q96L34 MARK4  2 11.40 0.000136 2.85 Cytoplasm  
Q9Y3F4 STRAP  1 10.70 0.000349 2.99 
Cytoplasm, 
nucleus  
Q6NSJ2 PHLDB3 1 9.44 0.000226 2.32 Unknown 









A1X283 SH3PXD2B  1 5.37 0.000273 2.94 Cytoplasm  
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